Movie review: Doc Human Nature strikes a nerve in the age of coronavirus – Milford Daily News

Documentary "Human Nature" examines how gene editing can help - and hurt - humanity.

If youre familiar with the Replicates from Blade Runner, the velociraptors from Jurassic Park or the genetic engineering so chillingly laid out in Aldous Huxleys novel Brave New World, youll be fascinated by how much science fiction has become science fact in Adam Bolts Human Nature. And its all due to CRISPR (pronounced crisper), a gene-altering technology that not only could facilitate designer babies, but possibly play a central role in putting the clamps on another acronym, COVID-19.

That timeliness is obviously on the side of Human Nature, a snazzy-looking documentary using sparkling graphics and top geneticists, journalists and one very adorable sickle-cell anemic to spell out a complicated subject in compelling, easy-to-grasp terms. But that same timeliness also works against it, given how now is not an advantageous moment for the films commercial aspects amid a landscape of shuttered theaters and a frightened populace whod like to avoid anything to do with medicine and science as sources of entertainment.

Yet, that double-edged sword fits snuggly in the wheelhouse of CRISPR (short for clustered regularly interspaced short palindromic repeats), a microorganism able to locate and repair defective DNA, as well as fend off invading viruses like COVID-19 by acting as a defense shield mimicking the offenders own DNA. But like the Internet, a revolutionary breakthrough for which CRISPR is often compared, theres a serious downside involving the morality of whether humans should have the right to, as the film calls it, play God. Namely, should parents be allowed to treat an embryo the same way theyd approach ordering a pizza? Well have the regular with blue eyes, blonde hair and an IQ of Einstein. Oh, and could you throw in some immense athletic ability, too?

Clearly, CRISPR has the potential to put us at the mercy of the type of mad scientists weve become accustomed to in just about every Bond film ever made. One geneticist, whose very name, Jennifer Doudna, includes DNA, admits having had a nightmare in which she comes face-to-face with Adolf Hitler! Are we willing to toy with the very real prospect of creating a master race?

Thats just one of the troubling questions Bolt confronts you with while weighing the pros and cons of a new frontier brimming in possibilities and danger. Personally, I come down on the side of CRISPRs benefits, particularly after meeting David Sanchez, a teen with sickle cell thats spent about half of his young life in hospitals receiving precious blood transfusions. Hes smart, personable and amazingly brave, so much so, you cant help but be all in when CRISPR offers him a chance at a more normal life. Yet, hes just as quick to recall to how hes learned to embrace -- even appreciate -- his illness because its made him a better, more resourceful kid, insights he would not have acquired had CRISPR been available when he was in utero. See? Hes torn, too.

Do we embrace a discovery wielding the promise of curing and preventing cancers and birth defects, or shun it for its ability to rob us of our unique individuality? Its a compelling argument I frankly wish Bolt had expanded more upon in his movies all-too-brief 90 minutes. But whats here is more than enough to spark a multitude of kitchen-table conversations about where we should set the limits on science, and more importantly, who should be making those decisions.

Given the disarray COVID-19 has put the world in, now probably isnt the time for us to evaluate, especially when CRISPR could well determine our fate by ridding our planet of a crippling plague. But what about after? Will, as Trump is fond to say, the cure be worse than the disease? Its a question for which Human Nature holds no answers, only utopian and despotic possibilities well be forced to uneasily choose between when and if the time comes.

More here:

Movie review: Doc Human Nature strikes a nerve in the age of coronavirus - Milford Daily News

The PEN Pod: Reimagining the Future with Jamie Metzl – PEN America

How prepared do you think we were for this moment of social distancing and for this global moment of hunkering down amidst uncertainty?In terms of social distancing, weve been social distancing; weve been virtualizing our lives since at least the advent of the telegraph in the 19th century. We have this idea of distance even now, where were communicating from away and communicating to others. But we also, as humans, have this deep need for physical connectivity. We are not virtual beings. And so, emotionally, were not ready for it. All of these structures for physical connectivity are gone, at least temporarily. Were almost in this Battlestar Galactica remake moment where were having to reconceptualize space and community. Its not that we will become un-physical beings, but were gonna have to figure out different ways of virtually sharing emotion and connectivity, at least until this danger passes.

Thats why organizations like PEN that are so focused on values are so critical, because these are the conversations that we have to have. Were going to have this incredible technology, but its up for grabs whether these technologies will be used to help or harm us.

You wrote at CNN.com about the human need for intimate physical connectivity. Can technology be a substitute for that? It seems like probably not.It cant be a substitute, but it can be a complement. And again, in our best possible world, I, for one, would love to live in some kind of hippie commune with real people there, and I also live, like many people, this global life where my friends and contacts are distributed around the world. I think we need to find that balance. But at times like this, our lives are becoming and feeling more virtual. And yes, theres a loss, and I think many of us are mourning that loss. But this is the world that we have now, and we have to make the most of it. Theres a lot of simple things that people can do. Make a list of all the people who you love and care about in your life, all the people who you think may be feeling isolated or alone, and just create a schedule of reaching out to them. My girlfriend and I are doing a virtual tea party with friends on Sunday where were gonna make tea, theyre gonna make tea, were gonna connect on FaceTime. We have to think of how we might do things differently. But its also not the case that when this crisis ends, society is just going to snap back to where it was, and were going to say, Wow, that was a crazy experience. Theres something happening now that is going to last beyond this.

What are some things that could be irrevocably different about our culture and the way we work and live, as a result of this moment?Were for sure not going fully back on virtualization. Were going to do things differently. Our sense of space is going to be different. A lot of people who are now working from home arent going to go back to physical offices because once companies figure out how they can work in this way, itll just be cheaper to have people stay at home. Were certainly going to change the way we think about global public health. If you asked a regular person, Wouldnt it make sense to have a super empowered World Health Organization with a global surveillance system that whenever any trip wire was hit, youd have an emergency response team that would fly to wherever that was and they would set up a command center and do what needed to be done? They would say, Yeah, dont we have that? And the answer is we dont. Because we have starved organizations like the WHO, because we have states that are demanding a level of control that doesnt make sense in our world of global challenges. One of the things that Im working on very, very actively now is imagining a third leg of the global political stool in addition to states and international institutions, and that is the democratic expression of the needs of our common humanity. It seems like its this big, crazy idea. But in these negotiations, no one is saying, Hey, climate change affects all of us; destroying our oceans affects all of us; global pandemics affect all of us. Who is standing up to help humanity? And thats what I think we need now.

I feel like Im at war from the battlestation of my office here on 81st Street in New York, so Im pretty focused on reading what I need to read now.

In Hacking Darwin, you wrote about genetics, you wrote about changing our genetic identity, perhaps to yield cures for diseases. Are you more or less optimistic about the potential for genetic science and cures than you were before?Im extremely optimistic. We are facing an enormous challenge today, but we now have almost godlike capacities to read, write, and hack the code of life. And those tools, Im firmly convinced, are going to save us, and were going to figure out treatments and were gonna have a vaccine not just for this, but for all kinds of challenges in the future. But these technologies dont come with a built-in value system. All technologies are value-neutral. Its up to us to determine what are the values that will guide the application of our most powerful technologies, and thats the issue. Thats why organizations like PEN that are so focused on values are so critical, because these are the conversations that we have to have. Were going to have this incredible technology, but its up for grabs whether these technologies will be used to help or harm us.

Finally, what are you reading, watching, or listening to right now?I would advise people at times of crisis like this to read poetry and literature. Im trying to do a little bit of that, but Im just all in and obsessed. Just last night I finished this incredible book, Spillover, by the amazing journalist David Quammen. And thats about zoonotic viruses like this, and our experiences in the past. Im now reading Betrayal of Trust by Laurie Garrett, which is about the destruction of our public health infrastructure. So when this is done, Im just going to beand I myself am a novelistback to reading the novels that I love so much. Maybe Ill read Proust and start thinking about Maman and her madeleine. But for now, I feel like Im at war from the battlestation of my office here on 81st Street in New York, so Im pretty focused on reading what I need to read now.

Wed like to know what books youre reading and how youre staying connected in the literary community. Click here to leave a voicemail for us. Your message could end up on a future episode of this podcast!

LEAVE A MESSAGE

See the original post here:

The PEN Pod: Reimagining the Future with Jamie Metzl - PEN America

10 Biotech Winners And Losers In Q1 – Benzinga

The quarter was brutal to say the least for most asset classes amid the coronavirus (COVID-19) pandemic. The S&P 500 Index was down about 20% for the quarter.

Amid the market mayhem, some health care stocks defied the downturn, thanks to announcements concerning development of drug/vaccine/diagnostic tests for new coronavirus.

Focusing on biotechs (leaving out diagnostics stocks), here the top five winners and losers for the quarter.

Benzinga is covering every angle of how the coronavirus affects the financial world.For daily updates,sign up for our coronavirus newsletter.

Genprex Inc (NASDAQ: GNPX): (+656.25%)

After ending 2019 in penny stock territory, shares of this gene therapy company began to gain ground after the company announced Fast Track Designation for its immunogene therapy in combination with AstraZeneca's(NYSE: AZN) Tagrisso for treating lung cancer. The momentum accelerated after it signed an exclusive agreement to license a diabetes gene therapy from the University of Pittsburgh.

After topping $7 in late February, the stock came off the highs amid the COVID-19 sell-off and managed to end the quarter with huge gains.

Vaxart Inc (NASDAQ: VXRT): (+405.71%)

Vaxart is a COVID-19 play and much of the quarter's gains were achieved on the back of the experimental oral vaccine candidate it's developing in partnership with Emergent Biosolutions Inc (NYSE: EBS).

Ibio Inc (NYSE: IBIO): (+324%)

Ibio, which develops human therapeutic proteins using advanced genetic engineering, joined the fray for a COVID-19 vaccine, which explains the surge in the stock.

Novavax, Inc. (NASDAQ: NVAX) (+241.2%)

Novavax was the beneficiary of dual catalysts: a COVID-19 vaccine in development and positive late-stage readout for its flu vaccine.

Trillium Therapeutics Inc (NASDAQ: TRIL): (+192.23%)

Thisimmuno-oncology company did not have much developments to justify its gain for the quarter.

Following a jump of about 63% in a single session in late February, the company issued a statement thatsaid "it is not aware of any material, undisclosed information related to the company that would account for the recent increase in the market price and level of trading volume of its common shares."

Related Link: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Milestone Pharmaceuticals Inc (NASDAQ: MIST): (-88.51%)

This cardiovascular-diseases-focused biopharma was cruising along fine until COVID-19 sell-off started in March. The real punch came from an adverse clinical readout.

Novan Inc (NASDAQ: NOVN): (-84.97%)

Novan, which leverages on nitric oxide's naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat various diseases, fell steeply at the start of the year. The trigger was a late-stage readout of its SB206 in molluscum contagiosum, which showed that the pipeline asset did not achieve statistically significant results for the primary endpoint.

The stock did not recover from this onslaught.

Acasti Pharma Inc (NASDAQ: ACST): (-84.49%)

Acasti also succumbed to a negative clinical readout for its lead prescription drug candidate CaPre, which did not achieve statistical significance for the primary endpoint of a late-stage study that evaluated it for treating elevated levels of triglycerides.

The company is now seeking FDA guidance for unblinding data from another Phase 3 study, and therefore expects a delay in reporting of topline results until the third quarter.

Salarius Pharmaceuticals Inc (NASDAQ: SLRX): (-81.98%)

This oncology-focused biotech gradually declined through the quarter, with some steep sell-off materializing amid its presentation at the BIO CEO & Investor conference in mid-February.

Amarin Corporation plc (NASDAQ: AMRN): (-81.34%)

Amarin shares, which ran up ahead and after the late-December FDA verdict on its application seeking label expansion for its fish oil pill, pulled back in January. The weakness intensified through the market meltdown. A negative court ruling sent the stock reeling this week.

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original:

10 Biotech Winners And Losers In Q1 - Benzinga

Making the Most of a CDMO Relationship – Genetic Engineering & Biotechnology News

Pharma and biopharma companies dont want to work on their relationships. These companies want their relationships to work for them. Fair enough. Still, when it comes to relationships with contract manufacturing and drug development organizations (CDMOs), pharma and biopharma companies cant avoid intimacy. These relationships are rewarding to the extent pharma and biopharma companies are clear about their needs and the kinds of associations consistent with those needs.

Typically, the most pressing need is keeping costs down. But other needs are important, too. These include expertise with specialized technologies, challenging drugs, and complex formulations. Identifying needs will help pharma and biopharma companies decide whether their CDMOs should help with discrete activities or provide complete, end-to-end services. Pharma and biopharma companies may also want their CDMOs to help with business strategy and regulatory compliance.

Besides identifying potentially compatible CDMO partners, pharma and biopharma companies need to build CDMO relationships characterized by mutual trust. Here again, clear communication is essential. It can help both parties in a CDMO relationship resolve misunderstandings and overcome unanticipated challenges together. For a fuller discussion of the ways CDMO relationships can benefit from clear communication, see the rest of this article, which presents various pointers and perspectives from CDMO experts.

Thierry Cournez is head of end-to-end solutions at MilliporeSigma, which offers a comprehensive portfolio of high-quality products and services, including testing services, for biopharmaceutical development. According to Cournez, most emerging biotech companies that have very early data and need to take their molecule to commercialization dont have all the expertise in-house that they need to navigate the entire process. One major trend is complete services, as opposed to la carte offerings.

MilliporeSigmas Plug & Play Upstream Development Service eliminates the need to work with multiple vendors for upstream development, relieving bottlenecks and reducing time to clinic. The service covers cell line development from DNA transfection to cell banking. Process development activities, which run in parallel, start when the company receives material from the first clones.

Cournez says that two services that will continue to be important in pharmaceutical development are process development and analytical services. A robust process is critical for manufacturing success, he explains, and analytical services are the foundation that supports the entire life cycle of biologics.

A trend toward all-in-one CDMO services has also been observed by Richard Shook, director of drug product technical services and business integration at Cambrex. Any time a client has to go to multiple vendors, it creates a lot of seams and communication problems, he points out. A lot of dots are not connected. Critical items can be lost, especially internal knowledge. When a client works with a single vendor, he stresses, the partners create a knowledge base that can be carried forward with the project. Cambrex provides drug substance, drug product, and analytical services across the entire drug lifecycle.

Fujifilm Diosynth Biotechnologies (FDB) is a division of Fujifilm that focuses on biopharmaceutical contract manufacturing, especially drug substances for biologics. That includes cell culture and fermentation, development and manufacturing, and advanced therapies like gene therapy. Fujifilms director of strategic business development, Daniel DeVido, PhD, says there is growing interest in gene therapy products and gene modified cell therapies.

In the area of viral vectors, new products on the market such as Luxturna (from Spark Therapeutics) and Zolgensma (from Novartis) have moved that sector of the industry forward. Newly approved chimeric antigen receptor (CAR) T-cell therapies, such as Kymriah (from Novartis) and Yescarta (from Kite Pharma) are also injecting energy into the field. And monoclonal antibodies have been going strong for the last 10 to 15 years, with approximately 80 therapies approved and on the market.

The industry is well funded right now, DeVido points out. A lot of companies are pushing candidates forward.

That increased demand for cell culture services brings new technical challenges. Everybodys looking for increased titers, DeVido emphasizes. For gene therapy, yields and titers are much less than they are for cell culture, so everybodys looking for the next thing that will get gene therapy to produce on the scale that monoclonal antibodies are on now.

Lonza offers a range of CDMO services. Karen Fallen, the companys head of mammalian and microbial development and manufacturing, says that Lonza works with companies from several different segments, including small and virtual companies that have limited in-house resources and capabilities. A lot of them are really focusing on the science, she notes. Theyre looking for preclinical and clinical services.

In Lonzas view, some of the trends among the smaller companies are due to larger Series A financings. In past years, Series A deals would have been $10 or $15 million, but now they are running higher, up to $70 or $80 million. They have different ambitions now, Fallen points out. They want and are able to take the molecule further along the supply chain, even to launch. They want to stay with Lonza longer before they partner up with large pharma and/or out-license these molecules. She adds that Lonzas customers also have more complex molecules in their pipelines.

Lonzas other big segment consists of large pharma companies. They have assets, and they have experience, she says. What theyre looking for now is newer technologies, with newer modalitiesbioconjugation, highly potent small molecules, or cell and gene therapies, for example.

Almac Group provides an extensive range of contract development and manufacturing services across the drug development life cycle. The increased interest in pediatric formulations is driving a demand for mini-tablets, especially those in stick-pack dosage form. The rapidly expanding oncology space, by its nature, creates a need for CDMOs that have extensive capabilities in processing highly potent active pharmaceutical ingredients at the small-to-medium scale.

Were seeing an industry trend toward higher value, lower volume products, says Jonas Mortensen, vice president of business development at Almac. Our clients are asking us to take on commercial supply of their product, often at, or close to, the same scale we had previously provided for their clinical studies.

To meet these new needs, Almac has installed multiple stick-pack machines across its sites in the United Kingdom and the United States. Almac is also finalizing the qualification of a dedicated suite of eight processing rooms and equipment solely designed for, and dedicated to, processing of highly potent active pharmaceutical ingredients.

Mortensen anticipates that some near-term trends in CDMO services will include supply chain risk mitigation, end-to-end services, and GMP floor space. CDMOs, he points out, are increasingly being asked to demonstrate their ability to support multisite supply strategies through global facilities or act as a secondary site of manufacture.

Communication is a common theme when it comes to recommendations for working with a CDMO. MilliporeSigmas Cournez says that biotech companies should choose a CDMO that has the most experienced people in-house. Doing so can help biotech companies avoid having to deal with multiple vendors. He also recommends having a dedicated project manager who can provide transparent communication with the vendor and connect with subject matter experts in case of unexpected changes.

Good communication also contributes to transparency in a project. Project transparency is really important, insists Cambrex Shook. That can be limited due to the competitive landscape of the project.

If problems arise during project execution, ownership and communication is really important. If its not there, losses occur and there are timeline setbacks. This could impact the scope, and once you get off scope, [it takes] money and resources to get back on track.

An illustration of the importance of communication comes from Catalent, a company that offers a range of CDMO services, including its recently introduced GPEx Boost technology for cell line development. Michael Riley, vice president and general manager of biologics at Catalent, says that in a program the company is currently working on, a customer was on a highly accelerated path to a product filing for a fast-track product. Catalent was working with regulatory authorities to characterize the companys manufacturing process and move toward validation of that process. To do that, Riley explains, we had to have very robust conversations between multiple functions within our organization and their organization from a quality and development standpoint.

Trust can be a delicate issue in relations between a CDMO and a customer. To illustrate this point FDBs DeVido describes a face-to-face discussion that the company had with one of its customers. This discussion, which took place in FDBs office in Cambridge, MA, resolved some contractual disagreements. We were able to sit around the table and go through the legal issues, DeVido recalls. We cleared up a lot very quickly.

When you sit down face to face and have good discussions, he says, everyones a little more comfortable. Even though people may feel theyre not completely safeguarded from a one-in-a-million occurrence, they may feel comfortable the two parties are going to work together through whatever the issue is.

DeVido said that once youve selected a CDMO, its important to be transparent and trust the company. Youve done your due diligence, he proposes. Now trust your selection and the system theyre operating in.

Benefits of working with an experienced vendor can go beyond development and manufacturing. Cournez says that in one instance, an emerging biotech customer had the opportunity to engage in licensing discussions with a large pharmaceutical company. Because the emerging biotech was small, we hosted the large pharma company at one of our sites and ran the due diligence, which was a great success, he relates. This former emerging biotech now funds many different programs because of the success of their first molecule.

Some vendors warn that business strategies can backfire. Focusing too much on price and speed to market can be risky when researching or working with CDMO/CMO partners, according to Cournez. The service provider must simplify the process and reduce touchpoints throughout the process.

Mortensen says that due to the significant investment required in resource and training, many smaller biopharma companies often do not have a regulatory affairs department of their own. Therefore, its critical for sponsors to recognize the consultative benefit CDMOs bring to the table as an extension of their company to help fill in any regulatory knowledge gaps. This timely advice, integrated with early- and late-stage development, can enable a sponsor to adequately prepare, ensuring little or no delay when bringing its products to market.

Read the original post:

Making the Most of a CDMO Relationship - Genetic Engineering & Biotechnology News

China, America, COVID-19 and the Mindless Conspiracy Theories, By Simbo Olorunfemi – Premium Times

there little or nothing in form of evidence in support of the claim that COVID-19 was genetically engineered in the laboratory. Dr. Trevor Bedford, a leading expert in the field, dismissed the claim of genetic engineering, telling Financial Times that the mutations in the virus are completely consistent with natural revolution.

Since the outbreak of COVID-19, a raft of conspiracy theories has been floating around. That is not unexpected. One, it is a pastime for some. Two, China is largely misunderstood by even the informed, not to talk of Western conspiracists with a worldview constrained by provincialism. But I seriously did not think that these wild conjectures would make it into the mainstream of public discourse, especially in our part of the world, with all sorts of elaborate, albeit misleading, narratives being woven around these theories. It is strange.

However, in putting what is playing out in the proper context, the first thing to recognise is that this pandemic, as overwhelming as it is, was not unforeseen as many assume. A September 2019 Report by the Global Preparedness Monitoring Board (GPMB) co-convened by the World Bank and the World Health Organisation (WHO) had warned about the growing possibility of a global pandemic, while highlighting the lack of preparedness by the world for it.

It says, The chances of a global pandemic are growing. While scientific and technological developments provide new tools that advance public health (including safely assessing medical countermeasures), they also allow for disease-causing microorganisms to be engineered or recreated in laboratories. A deliberate release would complicate outbreak response; in addition to the need to decide how to counter the pathogen, security measures would come into play limiting information-sharing and fomenting social divisions. Taken together, naturally occurring, accidental, or deliberate events caused by high-impact respiratory pathogens pose global catastrophic biological risks.

The report was categorical in its position that the world is not prepared for a fast-moving, virulent respiratory pathogen pandemic. The 1918 global influenza pandemic sickened one third of the world population and killed as many as 50 million people 2.8% of the total population. If a similar contagion occurred today with a population four times larger and travel times anywhere in the world less than 36 hours, 50 80 million people could perish. In addition to tragic levels of mortality, such a pandemic could cause panic, destabilize national security and seriously impact the global economy and trade.

A lot of the accusations being peddled centre around a supposed secrecy by the Chinese and a mismanagement of the outbreak, especially at the initial stage. But these allegations fuelled by the Western media do not find space in the report of the WHO-China Joint Mission on Coronavirus disease, consisting of 25 national and international experts from Nigeria, China, Germany

There is little doubt that what has played out mirrors what is in the report. So, if a report presented by the GPMB, of which Dr. Anthony Fauci, the director, National Institute of Allergy and Infectious Diseases, United States of America, is one of the three Americans on the 15-man Board, what excuse has the United States of America for his lack of preparedness, no matter what might have been the source of the pathogen? How is it that with such advanced notification, America would be where it is now, looking at the loss of 100,000 to 240,000 lives in a best-case scenario and the death of one million Americans in a worst-case scenario? What has that got to do with China?

A lot of the accusations being peddled centre around a supposed secrecy by the Chinese and a mismanagement of the outbreak, especially at the initial stage. But these allegations fuelled by the Western media do not find space in the report of the WHO-China Joint Mission on Coronavirus disease, consisting of 25 national and international experts from Nigeria, China, Germany, Japan, Korea, Russia, Singapore, the United States of America and the World Health Organisation (WHO), which was in China for nine days in February to inform nation and international planning on next steps in the response to the ongoing outbreak of the novel coronavirus disease (COVID-191) and on next steps in readiness and preparedness for geographic areas not yet affected. It did not allege secrecy or lack of cooperation on the part of the Chinese. Rather, the effort by the Chinese was applauded, just as the director-general of the World Health Organisation has cited China as deserving of gratitude and respect.

A review of the timeline of the outbreak leaves one wondering about the basis of much of the allegations against China. What started as a cluster of pneumonia cases of unknown cause towards the middle of December was declared a public health emergency by the end of the month, with the world Health Organisation having been notified. A novel coronavirus was isolated by the China Centre for Disease Control (CDC) on January 7 and with the pathogen identified, full genome sequences of the new virus were immediately shared with the WHO and the international community. The first case of COVID-19 was detected on January 13 and a set of nucleic acid primers and probes for PCR detection for COVID-19 were released on January 21, which makes much of what is being passed around as deliberate secrecy on the part of China difficult to understand.

Indeed, some of the theories which blame China situate their arguments on the origin and the mode of transmission of the virus. While COVID-19 has been established as a zoonotic virus, with phylogenetics analyses undertaken alongside available full genome sequences suggesting bats as the reservoir of the COVID-19 virus, yet reports have it that the intermediate host(s) has not yet been identified. While the focus of the world through the lens of the media has been on the Seafood Market in Wuhan, however, according to reports, there is no evidence so far that the origin of SARS-CoV-2 was from the seafood market. But also is there little or nothing in form of evidence in support of the claim that COVID-19 was genetically engineered in the laboratory. Dr. Trevor Bedford, a leading expert in the field, dismissed the claim of genetic engineering, telling Financial Times that the mutations in the virus are completely consistent with natural revolution. The argument that the China stands to economically benefit from the outbreak is rather tenuous. It flies in the face of logic.

The warning was there, alarm bells rang and the opportunity to make a quick readjustment in terms of preparedness and strategy offered itself with availability of the strategy and template deployed in China, which could be appropriated tinkered with for local adaptation. That did not appear to have appealed as a course of action to take for those who are apparently now in much need of it.

If anything, what should be of interest is the level of planning and preparedness by other parts of the world, following the outbreak in China. If the 2019 Global Preparedness Monitoring Board (GPMB) Report was not enough warning, that by the WHO-China Joint Mission on COVID-19 should have been taken seriously. But developments in many parts of the world, subsequent to the outbreak in China and what she did in terms of containment do not suggest that. While the report acknowledges that in the face of a previously unknown virus, China has rolled out perhaps the most ambitious, agile and aggressive disease containment effort in history with a treatment plan founded around the principle of Four Concentrations, which meant the concentration of patients, medical experts, resources and treatment into special centres, with a science and risk-based approach adopted to tailoring implementation of the containment strategy. Some of the advanced countries that experienced outbreaks thereafter came across as largely unprepared, failing to take on-board lessons from China, given that there has been a significant increase in knowledge, approaches and even tools through the rapid scientific work done in China within the seven weeks since this virus was discovered, but not much heed was paid to this.

The Joint Mission had warned, even as at the end of February, that much of the global community is not yet ready, in mindset and materially, to implement the measures that have been employed to contain COVID-19 in China (and that)achieving the high quality of implementation needed to be successful with such measures requires an unusual and unprecedented speed of decision-making by top leaders, operational thoroughness by public health systems, and engagement of society. Given the damage that can be caused by uncontrolled, community-level transmission of this virus, such an approach is warranted to save lives and to gain the weeks and months needed for the testing of therapeutics and vaccine development.

While warning that COVID-19 is spreading with astonishing speed and that outbreaks in any setting have very serious consequences for others, the mission advised that there is now strong evidence that non-pharmaceutical interventions can reduce and even interrupt transmission. But the concern was that global and national preparedness planning is often ambivalent about interventions of this nature. But it was emphatic that the time that can be gained through the full application of these measures even if just days or weeks can be invaluable in ultimately reducing COVID-19 illness and deaths.

The warning was there, alarm bells rang and the opportunity to make a quick readjustment in terms of preparedness and strategy offered itself with availability of the strategy and template deployed in China, which could be appropriated tinkered with for local adaptation. That did not appear to have appealed as a course of action to take for those who are apparently now in much need of it. The argument on the part of the experts had been for the high and middle-income countries to be rigorous with the recommended non-pharmaceutical measures to roll back transmission as that is vital to achieving a second line of defense to protect low income countries that have weaker health systems and coping capacities, it is an irony that some of the advanced economies have failed in this regard and it is now a case of ensuring that the setback in the countries with stronger health systems do not negatively set aback the progress that has been achieved by many of the low income countries, which simply opted to pay attention to the little things, falling back on their relative hands-on experience and consistency with catering to the base of the healthcare structure, due to the challenge of underdevelopment. These conspiracy theories only remind us of the danger of an infodemic that the world is presently faced with. They do not go far in covering the king who, unfortunately, has left himself uncovered.

Simbo Olorunfemi works for Hoofbeatdotcom, a Nigerian Communications Consultancy and publisher of Africa Enterprise. Twitter: @simboolorunfemi

Related

Read the rest here:

China, America, COVID-19 and the Mindless Conspiracy Theories, By Simbo Olorunfemi - Premium Times

Podcast: Science writer Michael Specter on what you should know about the coronavirus, food security and GMOs – Genetic Literacy Project

Science writer, New Yorker contributor and author of the book Denialism Michael Specter joins Felix Salmon on the Slate Money podcast to break down the ongoing coronavirus crisis.

Specter explains how the virus spreads, potential food and medicine shortages it could cause and the possibility of developing immunity to infection. While the pandemic has shocked most of the world, Specter argues the only thing that should surprise anyone is the inept response of policy makers to the outbreak, particularly in the United States.

Specter also challenges some common misconceptions surrounding biotechnology, including the idea that GMOs are unnatural. Concerns about monoculture, the practice of growing a single crop like corn, on the other hand, are valid, Specter says. But that issue has nothing to do with genetic engineering. Its a problem that could be solved by a change in government policies: ending subsidies to corn and soybean growers. However, there are trade offs involved, and eliminating monoculture farms isnt the simple decision it seems.

Listen the to the original podcast

Read the original here:

Podcast: Science writer Michael Specter on what you should know about the coronavirus, food security and GMOs - Genetic Literacy Project

Timeline Shows 3 Paths To COVID-19 Treatment And Prevention (INFOGRAPHIC) – SynBioBeta

In uncertain times, we are witnessing one of the greatest moments in the history of science.

Scientists are breaking speed records in their race to develop treatments for the new coronavirus. Some are panning through old molecules hoping to find effective drugs. Others are applying the latest breakthroughs in synthetic biology to engineer sophisticated treatments and vaccines.

Ive previously talked about somesynthetic biology companies that are racing to create treatments. Others like Mammoth Biosciences are developingmuch-needed testing. Every day brings additional reports of the latest breakthroughs from around the world. But how can we make sense of all this information?

To provide a big-picture perspective,SynBioBetaandLeaps by Bayerhave partnered to help visualize the overall progress of the research community. At the heart of the project isan infographic showing the timeline to the various treatments and preventions (click here to download it).Its based on data from The Milken Institute, which recently releaseda detailed trackerto monitor the progress of each of the more than 60 known COVID-19 treatments and preventions currently in development.

One takeaway: the progress to develop coronavirus treatments and preventions is moving at an unprecedented pace, with historic records being broken nearly every week.

The crisis response from the global biotech community has been truly inspiring, says Juergen Eckhardt, SVP and Head of Leaps by Bayer, a unit of Bayer AG that leads impact investments into solutions to some of todays biggest challenges in health and agriculture. We are excited to partner on this visual timeline to help a broader audience understand how and when scientific innovation may bring us through this deeply challenging time.

There are standard stages to getting a drug approved. In Phase 1 trials, a drugs safety is assessed in a small group of healthy subjects. In later stages (Phase II & III), efficacy is measured in a larger number of people, often versus a placebo. The situation with COVID-19 is predicted to become so dire so quickly, however, that many are looking to fast-track testing. This could include granting experimental drugs expanded access, for compassionate use, which would allow physicians to give them to patients who are critically ill before testing is complete.

The fastest way to safely stop COVID-19 would be to discover that an already-approved medication works against it. Repurposed drugs do not require the same extensive testing as novel medicines and may already be available in large quantities. The Milken Institutes tracker identifies 7 candidate drugs in this category.

One is the malarial medicine chloroquine, which in recent days has beentouted by someas a possible miracle drug against the coronavirus. German pharmaceutical company Bayer last week donated three million tablets of chloroquine to the U.S. The FDA and academics are togetherinvestigating whether it can provide reliefto COVID-19 patients.

There are hundreds if not thousands of other FDA-approved drugs on the market that are already proven safe in humans and that may have treatment potential against COVID-19, so many scientists are rapidly screening the known drug arsenal in hopes of discovering an effective compound.

Antibodies are proteins that are a natural part of the human immune system. They work around the clock in blood to block viruses and more. The problem at the moment is that because the novel coronavirus (known as SARS-CoV-2) is new, no one has had time to develop antibodies against it. No one, that is, except those who have recovered from COVID-19.

Antibodies taken from those people could help patients who are still infected. Such patient-to-patient transfers can be performed without extensive testing or lengthy approval processes so long as standard protocols are followed. It is yet unknown whether this treatment option will work for COVID-19, nor whether there will be enough recovered donors to deal with the infection at scale.

To improve this process, companies like Vancouver, Canada-basedAbCelleraare applying new biotechnologies.

AbCellera is using proprietary tools and machine learning to rapidly screen through millions of B cells from patients who recovered from COVID-19. B cells are responsible for producing antibodies. The company hasannounced a partnershipwith Eli Lilly on this project and aims to bring its hottest antibodies those that neutralize the virus to the clinic.

AbCelleras platform has delivered, with unprecedented speed, by far the worlds largest panel of anti-SAR-CoV-2 antibodies, said Carl Hansen, Ph.D., CEO of AbCellera, in a statement. In 11 days, weve discovered hundreds of antibodies against the SARS-CoV-2 virus responsible for the current outbreak, moved into functional testing with global experts in virology, and signed a co-development agreement with one of the worlds leading biopharmaceutical companies. Were deeply impressed with the speed and agility of Lillys response to this global challenge. Together, our teams are committed to delivering a countermeasure to stop the outbreak.

James Crowe at Vanderbilt University is also sifting through the blood of recovered patients. Using a new instrument called Beacon from a company calledBerkeley Lights.Crowes teamhas been scouring through B cells to find antibodies that neutralize SARS-CoV-2. The technology behind this project was developed in recent years with funds from the Department of Defense.

Normally this would be a five year program, Crowe told me. But in the rapid process his team is following, animal studies could be done in as fast as two months.

This morning,Berkeley Lightsannounceda Global Emerging Pathogen Antibody Discovery Consortium (GEPAD) to attack COVID-19and other viruses. It is partnering with Vanderbilt University, La Jolla Institute for Immunology, and Emory University to accelerate the work above to the broader research community.

This collaboration also included commercial partners, includingTwist Bioscience, who synthesized DNA for the project.

Our mission is to provide the raw material needed for biologists to make breakthroughs, said Twists CEO Emily Leproust. If DNA is needed, we want to make it, quickly and perfectly

Another company that specializes in DNA synthesis,SGI-DNA, is offering its tools at much reduced cost to researchers developing COVID-19 treatments. The company said that people from around the world are coming to them for help.

There is zero time to waste,saidTodd R. Nelson, Ph.D., CEO of SGI-DNA. He said that researchers need synthetic DNA and RNA, which its Bio-XP machine can provide in as little as eight hours.

Nelson continued, In a matter of a day or two, we have built the genes thought to be critical to the development of successful vaccines against SARS-CoV-2. SGI-DNA has made them available in the form of different genetic libraries, which researchers can use to find druggable targets in a matter of hours, dramatically accelerating the time to market for therapeutics and vaccines.

Beyond searching for antibodies in recovered patients, biotechnologists have other tricks up their sleeves.

One approach involves genetically engineering laboratory mice to mimic the human immune system. These animals can then be presented with the virus or parts of the virus and allowed to recover. The hope is that their B cells would then produce effective antibodies. Because this happens in a controlled setting, biologists can better understand and engineer the process.

A company calledGenScriptwaspursuing this strategyas early as February 4, when police escorted 8 transgenic mice immunized with the 2019 nCoV antigen to research labs in China. In 12 hours, its researchers successfully found specific antibodies in the mice that could recognize the novel virus and potentially block it from binding to cells. In less than 24 hoursagain using Berkeley Lights new Beacon instrument for working with thousands of individual, live cellsGenScript completed a series of steps that would have taken three months using previous technology.

Yet another approach involves computational approaches and artificial intelligence. Firms likeDistributed Bioare using computers to reengineer antibodies to better target SARS-CoV-2. The company is optimizing antibodies that are known to target SARS-CoV-1, the virus behind the 2003 outbreak of SARS.

We believe broadly neutralizing antibodies with engineered biophysical properties will become key weapons to win the war against all coronaviruses said Jake Glanville, CEO of Distributed Bio.

Vaccines work by simulating infection, which allows the body to mount its own defense against a virus. Effective vaccines take time to develop, and they can take even longer to test. But recent progress in biotechnology is again accelerating these efforts.

Notably,Modernahas launched a Phase 1 vaccine trial against COVID-19 in record time. Patients in Seattle have already begun receiving injections of an experimental mRNA vaccine. Moderna cranked out doses of this and won approval from the FDA for testing in just 44 days an all-time record.

These programs show a massive focus on a common enemy, and a coming together of disparate firms.

Ginkgo Bioworks, a giant in the emerging field of synthetic biology,has announced a $25 million fund to help spur even more collaboration.The company is offering its laboratory equipment and know-how to anyone with a good idea of how to stop COVID-19. We dont want any scientists to have to wait. The pandemic has already arrived, so the time for rapid prototyping and scale-up is right now, said Jason Kelly, CEO of Ginkgo.

These effortsand the infographic aboveshould give you hope. Although we are all now living in uncertain times, we are also witnessing one of the greatest moments in the history of science.

Its a terrible time, and simultaneously a fantastic time to see the global science community working together to conquer this very hard and challenging disease, said Berkeley Lights CEO Eric Hobbs. We are also learning and developing the tools and technologies to ensure that we can react faster to the next threat, so that we dont get to this point again in the future.

Follow me on twitter at@johncumbersand@synbiobeta. Subscribe to my weekly newsletters insynthetic biology.

Thank you toIan HaydonandKevin Costafor additional research and reporting in this article. Im the founder ofSynBioBeta, and some of the companies that I write aboutincludingLeaps by Bayer,Mammoth Biosciences, Distributed Bio, Twist Bioscience, SGI-DNA, Genscript, Berkeley Lights, and Ginkgo Bioworksare sponsors of theSynBioBeta conferenceandweekly digestheres the full list of SynBioBeta sponsors.

Originally published on Forbes https://www.forbes.com/sites/johncumbers/2020/03/25/timeline-shows-3-paths-to-covid-19-treatment-and-prevention-infographic/

Read the original here:

Timeline Shows 3 Paths To COVID-19 Treatment And Prevention (INFOGRAPHIC) - SynBioBeta

Scientist says anti-epilepsy drug can be repurposed for Covid-19, writes to ICMR to test it – ThePrint

Text Size:A- A+

New Delhi:A leading scientist at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in New Delhi has found that valproic acid, an anti-epilepsy drug, can be repurposed and used for acute cases of Covid-19.

The scientist, Neel Sarovar Bhavesh, has written to the director general of the Indian Council of Medical Research (ICMR), the apex body in the field, to test valproic acid at the National Institute of Virology in Pune or any ICMR lab to find a quick solution to the coronavirus crisis.

The ICGEB is part of the research consortium working to find a cure and vaccine for Covid-19.

Valproic acid is an approved drug, whose patent expired recently. It is sold under brand names such as Depacon and Stavzor to treat epilepsy. The University of California has also validated the ICGEBs research findings it lists valproic acid as one of the molecules for repurposing and testing for use against the Covid-19 virus.

Also read: AI identifies potential drugs and a DNA vaccine in the works latest on Covid-19

Bhavesh, the head of transcriptional regulation at ICGEB, told ThePrint: We have performed high-throughput virtual screening (HTVS) of 1.2 million small molecules from the four databases, and later performed Energy calculation and molecular binding simulation. We found that valproic acid CoA may be repurposed to inhibit the RNA-dependent RNA polymerase of the virus.

We have written to the DG ICMR to test this molecule on cell culture and animal testing facilities, in combination with potent binding blocking molecules. Currently no one in India outside the NIV and ICMR has access to the Covid-19 virus, Bhavesh said.

About 1,100 strains of the novel coronavirus have been sequenced from around the world. We (in India) have around 700 confirmed positive cases, but only two virus sequences are available at the NIV. These sequences are different from each other, he explained.

Bhavesh revealed that after the publication of the ICGEB research, multinational pharmaceutical company GlaxoSmithKline contacted them.

However, Bhavesh said theres an urgent need for cooperation from government bodies like the ICMR and the NIV in terms of giving researchers access to the virus strains in India to test on.

There should be synchronisation in testing and developing. If NIV or any another research institution finds success, lots of patients can be cured and saved. The need of the hour is to find the solution. The NIV must cooperate with other institutions more generously, he said.

A day before, Union Biotechnology Secretary Renu Swarup also said in an interview that early solutions for the novel coronavirus can be found from repurposed drugs, and that developing new drugs would take time.

Also read: Old drugs, new trials hopes pinned on HIV, malaria, ebola, TB vaccines to fight Covid-19

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

More here:

Scientist says anti-epilepsy drug can be repurposed for Covid-19, writes to ICMR to test it - ThePrint

How the novel coronavirus is mutating, and if you should be concerned – ThePrint

Text Size:A- A+

Bengaluru/New Delhi: As the coronavirus outbreak continues to spread across the world, the cyberspace has been abuzz with claims that the Covid-19 strain in India is a less virulent mutation than the one travelling abroad. BJP leader and Rajya Sabha MP Subramanian Swamy and gastroenterologist D. Nageshwar Reddy are among those who have made such claims.

While Swamy quoted an American friend in a tweet last week to say the Covid-19 strain in India can be defeated more effectively by our bodys natural defense mechanism than the strains abroad, Reddy in an interview floated similar claims without quoting any research.

Some users responded to Swamys tweet posting a link to a study that they claimed supported his notion. But this study, which is yet to be peer reviewed, has faults of its own, including use of limited data.

A number of experts in the field have termed such assertions baseless. Dr Gagandeep Kang, executive director at the Translational Health Science & Technology Institute in Faridabad, called Reddys comments appalling & misleading.

As such claims circulate online, ThePrint highlights the science of virus mutation and whether you should be worried.

Also read:WHO says coronavirus outbreak in Europe could be approaching peak

The overarching problem is the use of the term Indian SARS-CoV-2 strain that is in itself misleading.

A strain is a sub-type of a virus, characterised by different cell surface proteins, eliciting a different immune response from other strains. A mutation, however, is very minor genetic errors in genome sequences made during replication that doesnt fundamentally change the nature or behaviour of the virus.

So far, only two isolates from India have been genetically sequenced. Both are from coronavirus patients in Kerala who had arrived from Chinas Wuhan in late January. The strains are nearly identical to the ones sequenced in Wuhan and cannot be identified as a separate Indian strain.

Anu Raghunathan, a scientist at the Council of Scientific and Industrial Researchs (CSIR) National Chemical Laboratory in Pune, told ThePrint that the researchers of the aforementioned study used computational biology to analyse the genomic data from different strains around the world.

Theinitial attempt of the team from the International Centre for Genetic Engineering and Biology, New Delhi, at analysing the virus strain is not sufficient to conclude that all Indian strains would have only one unique mutation, said Raghunathan.

The mutations themselves are composed of changes in base pairs.

The novel coronaviruss genome is made up of 30,000 base pairs, while a human genome contains over 3 billion. The small numbers make it easy for scientists to track changes and new lineages as they evolve.

To understand what these mutations mean for India, the country will have to sequence a much larger set of the viral isolates from the patients here.

Rakesh K. Mishra, director of CSIRs Centre for Cellular and Molecular Biology in Hyderabad, told ThePrint that his institute has the capacity to run the genome sequencing of the isolates from at least 500 people within a couple of weeks. This can help scientists decide the correct course of action for treating the disease.

For example, if a virus mutates too fast, vaccines being developed now will potentially become useless, and pharmaceuticals will have to constantly keep up with the mutations by developing new vaccines all the time, a financially unviable prospect.

Also read:China now wants people to shop, eat out while rest of the world locks down

Regularly switching up the genetic code is an essential part of how a virus evolves. Some viruses, such as the coronaviruses that cause flu, change their genetic code extremely rapidly. This is the main reason why its so difficult to find a vaccine for coronaviruses. They evolve quickly, making vaccines defunct.

The flu vaccine, now available and recommended especially for older people, needs to be taken annually for this reason. By the time the next season comes along, the vaccine is no longer effective on the circulating form of the virus.

Coronaviruses are ribonucleic acid (RNA) viruses, containing just RNA strands (single or double) as its genetic material. They have about 26,000 to 32,000 bases or RNA letters in their length.

RNA viruses mutate continuously. Such a mutation is what made SARS-CoV-2s jump from animals to humans possible.

The virus multiplies inside living organisms cells by creating copies for the RNA. However, the process it uses to make these copies is not perfect, and often introduces tiny errors in the sequence of letters much like a game of Chinese whispers.

The errors that do not help the survival of the virus eventually get eliminated, while other mutations get embedded. It is these mistakes that help scientists track how the virus travelled around different geographic locations.

For example, by genetically sequencing over 2,000 isolates of samples from different countries, scientists tracked how the novel coronavirusspread to different countries, and how the virus evolved and geographically mutated in different areas.

The word mutations often conjures images of humans with superpowers thanks to Hollywood movies but it doesnt mean the virus acquires superpowers. The genetic changes are normal in the evolution of the virus. In some cases, the changes are extremely rapid because the replication is not rigorous or thorough.

The only problem with mutations is the problem of development of vaccines, which would require constant upgrade.

Also read:Why asymptomatic coronavirus carriers arent as contagious but still a big danger

The novel coronavirus, unlike its cousins, mutates slowly. It seems to have a proofreading mechanism in place that reduces the error rate and slows down the speed of mutation. But the mutations are completely random.

One mutation that supports the virus replication and transmission from human to human or any other host sustains whereas the virus that cannot infect many eventually dies out, explained Shweta Chelluboina, clinical virologist at the Interactive Research School for Health Affairs in Pune.

These are random events and such a phenomenon has caused the outbreak in the first place.The newcoronavirushad mutated successfully enoughthat it jumped from animal tohuman, allowingit to infect manywith still no containment in sight, said Chelluboina.

There were reports earlier about how the novel coronavirus has mutated into two strains so far the original S-type which originated in Wuhan, and the subsequent L-type that evolved from the S-type and is more prevalent in countries like the US. Scientists at the Peking Universitys School of Life Sciences and the Institut Pasteur of Shanghai announced these findings.

The L-type is the more aggressive one, and spreads rapidly but is no more or less virulent than the S-type. The researchers urged everyone to take preventive measures because the mutation indicates that more could be coming.

But these arent really two strains as such. A strain is a genetic variant characterised by different forms of surface proteins. But the L-type and the S-type are not quite different enough to call them strains just yet. They are just mutations, referred to as types, according to the study.

To explain the lower population of S-type, the authors of the study suggested that human-adopted measures of curbing contact contained the S-type to the Wuhan region, and allowed the L-type to spread elsewhere uncontained. While the S-type emerged around the time the virus jumped from animals to humans, the L-type emerged soon after that within humans, the team suggested.

Experts think there is also a definite sampling bias for the L-type, which was just sampled more, and uniformly, resulting in higher representation. The mutations were discovered in a preliminary study, as cautioned by the authors as well, and was performed on a limited population of 103 samples.

The study is not peer-reviewed yet, and as most Covid-related studies are under the open community, is a pre-print for now. It was uploaded on 4 March.

These findings strongly support an urgent need for further immediate, comprehensive studies that combine genomic data, epidemiological data, and chart records of the clinical symptoms of patients with coronavirus disease 2019 (Covid-19), said the study.

The science is evolving rapidly, as more and more genome data is collected from around the world.

Newer research data gathered from genetic sequences uploaded to open source website NextStrain.org indicate that anywhere from eight to 18 different sequences of the coronavirus are making their way around the globe, according to researchers who have genetically sequenced over 1,400 isolates from around the world. These are extremely tiny differences within the viruses in their nucleotide sequences, and none of the sequenced groups seem to be growing any more or less lethal than others.

Most importantly, none of them are new strains despite their coverage as such in the mediaand subsequent clarifications by Nextstrain, who have the data for 2,243 SARS-CoV-2 genomes, of which 1,150 have minor mutations.

On Nextstrain, nearly every virus reveals a slightly different genome. But there are very few mutations and none are strong or vital enough to affect the way the virus spreads, attacks, or lives. The sequences are all named by location where they were first sequenced.

It is very common that during an outbreak, especially during a global pandemic, the genome sequence of earlier isolates from one particular geographical location will differ from that of the later isolates collected elsewhere, said Sreejith Rajasekharan, virologist and post doc at the International Center for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy, over an email.

This is what is observed in the current pandemic as well. The first sequence collected from positive patients in Rome, Italy was from a Chinese tourist. This and the one collected after, from an Italian citizen returning from China resemble those that were isolated in China, said Rajasekharan.

However, the ones isolated later in Lombardia and Friuli Venezia Giulia regions (in Italy) match the European clad and not the one from China.

The mutations in the virus are like moving targets, which cant be hit because they keep changing their genetic sequence.

Genome sequencing on a large scale can tell us whether viral isolates are different in different countries from what we saw from China. So this will help us decide whether the treatments being contemplated in those places will be applicable for our strains or not, Rakesh Mishra said.

It will also help decide if the different strains vary so much that developing vaccines may not be viable, Mishra said.

Some behaviours are unique in different strains like how we know that aged people are at high risk but we saw in India young people have also died, said Chelluboina. Some variations in the virus cause the virus to behave in a certain way.

The sequencing will provide a fundamental understanding of how to address the problem without it, the treatments are based on what is known of other viruses which may or may not work for the novel coronavirus, and also likely take up a long time.

That is why it is important to understand the sequence of the virus in local infections to know which countries have a similar virus, so that we can attempt to better predict the outcome, added Chelluboina.

However, Rajasekharan added, The general public needs not be concerned in this regard as the genome of SARS-CoV-2 is quite stable, and therefore the rate of mutation is low.

The novel coronavirus will continue to mutate and pose a challenge to researchers developing a vaccine. Nonetheless, the idea of viruses mutating is not something that needs to worry people in terms of their health when it comes to Covid-19.

Also read:Seasonal flu far more common than coronavirus, but its vaccine is not popular in India

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

Read this article:

How the novel coronavirus is mutating, and if you should be concerned - ThePrint

Mapfre to donate 5 million to Spanish National Research Council – Times of Malta

Mapfre will donate 5 million to the Spanish National Research Council (CSIC) to accelerate research in Spain and, especially, investigations related to COVID-19.

The contribution will allow a comprehensive study of this pandemic, deepen the knowledge of the virus and its transmission mechanisms, and promote not only a vaccine against it, but also a scientific basis to better protect the population against future pandemics.

This action is announced within the framework of a Mapfres strategy against COVID-19 based on three lines of action: protect people, safeguard economic activity, especially employment, and help society to overcome the impact in the medium and longer term.

The National Center for Biotechnology (CNB) of CSIC was already a pioneer, and decisive with its genetic engineering techniques, for the achievement of the SARS vaccine in 2002.

Companies, as corporate citizens, must also have a relevant role participating in public-private alliances such as this that allow the fight against the pandemic to be accelerated, said Antonio Huertas, Mapfre president.

It is at these times when we have to take firm steps that help society to overcome this extraordinary situation, and contribute to the way out of this crisis with the least possible impact. We are all called to coordinated action, we are very proud to contribute to the research that CSIC is leading, and we hope that more entities will join this effort to achieve the vaccine that the world population needs.

Mapfre also wants to vindicate the work of scientists and researchers not only at specific times like those present, but in general as an essential activity for the progress of individuals and societies.

Rosa Menndez CSIC president, said: This donation represents a considerable boost for the CSIC teams. We are already working to unravel the keys to the new coronavirus, but we are also launching more than 50 coordinated projects to jointly address the challenge posed by the pandemic. These are projects that range from biotechnology and diagnostic nanosensors to mathematical models to understand the spread of the disease. Mapfres support will allow us to accelerate these projects.

The donation will be made through Fundacin Mapfre, with immediate effect. Fundacin Mapfre is a non-profit entity that has been working for the benefit of society for more than 45 years, executing social actions aimed at the most vulnerable groups.

The Mapfre Group continues to deploy a broad action plan against the coronavirus in all the countries where it is present. In addition to the widespread implementation of teleworking, it is guaranteeing the service in essential coverage with the maximum protection measures for employees, collaborators and clients.

Likewise, the company has just announced a set of measures in Spain, worth 30 million, to protect the activity of self-employed and SMEs through the duration of the crisis: Mapfre will discount in its policies the part of the insurance premiums that cover the professional activity corresponding to the confinement period.

Independent journalism costs money. Support Times of Malta for the price of a coffee.

Read the original:

Mapfre to donate 5 million to Spanish National Research Council - Times of Malta

How far should genetic engineering go to allow this couple to have a healthy baby? – Sydney Morning Herald

Normal text sizeLarger text sizeVery large text size

One morning in 2005, Shelley Beverley woke up to find that she had gone deaf. She was 21, and living in Johannesburg with her older brother Neil. I was very scared, she says. It was just so sudden. She struggled through the rest of the day, hoping that her hearing would come back, but it didnt. In one sense, her hearing loss wasnt entirely a surprise: Beverleys grandmother had been deaf, Neil had lost his hearing when he was 13, and her mum, Mary, had lost hers when she was 32. We knew it ran in the family, she says, but I thought Id been lucky and not inherited it.

Beverley, 35, lives in Margate, a semi-rural district south of Hobart, with her husband James. The couple migrated to Australia from South Africa in 2010, looking for space, buying 2 hectares of lush green grass at the foot of a forested ridge near the mouth of the Derwent River. We love the wildlife here, says James, looking out the living room window. Weve seen pademelons, echidnas, quolls, blue-tongue lizards, even a Tassie devil. At dusk, hundreds of kangaroos emerge from the forest to gorge on the grass. Its very peaceful, says James. Its really helped us after everything thats happened.

Apart from their deafness, Beverleys family had largely enjoyed good health. Then, in September 2015, her mother, Mary, then 62, started experiencing fatigue and stomach pain. Doctors in Durban ordered a colonoscopy, but the procedure made her worse. Her feet became swollen and purple. Because of their hearing problems, Shelley and Mary had communicated mainly in text messages. But soon I began noticing that her wording got a bit funny, says Beverley. It didnt always make sense.

Loading

Beverley flew to Durban in February 2016, but by that time her mother could no longer talk or walk. She was so weak that she couldnt move her hands or lift her neck. Two days after Beverley arrived in Durban, her mother caught a virus that caused fluid to build up on her lungs. The doctors tried unsuccessfully to drain it. Shortly afterwards, she died. She weighed just 36 kilograms. It was so fast, Beverley says. And we were still in the dark about what she had.

Shortly before Marys death, Neil had also fallen ill. He developed a number of mysterious symptoms, including facial twitches and seizures. He kept falling over and tripping, and experienced vomiting and headaches so severe he lost his vision for weeks at a time. His behaviour became strange showering with his clothes on, and hallucinating.

One day, Dad was driving him around and Neil started talking to all these little people he thought were around his feet, says Beverley. Doctors in Durban had trouble diagnosing him, so they sent a biopsy to London, where he was found to have a type of mitochondrial cytopathy one of a large family of chronic and progressive diseases that affect the muscles, brain and nervous system. As the family soon learnt, the condition has no cure and no effective therapies. One of the common early symptoms is hearing loss.

Neil died in June 2017, aged 34, by which time Beverley had discovered she also had the condition. It was fear, so much fear, she says. She began experiencing symptoms, including migraines and vision loss. She has since developed diabetes, hypertension, gastro-paresis (when your stomach muscles dont work), and pharyngeal dysphagia (difficulty swallowing). Every time I get sick now, the flu or something, I think, When am I going to need a wheelchair or a feeding tube? When will my legs stop working?

Mito has taken everything from me, she says. If I die, at least James will still have a part of me.

Beverley has bright blue eyes and long, straight, ash-brown hair. Shes got a lazy left eye and uncommonly pale skin, which she attributes to her condition. Oh, and I had bunions out in 2010, she says, laughing wryly.

She doesnt know how long shes got left, but she is determined to make it count. She has joined mito awareness groups, and is an active member of the Mito Foundation, which supports sufferers, and funds research. She has exhaustively researched the condition and takes every opportunity to educate doctors. Youd be surprised by how little they know about it, she says.

But her overriding focus has been on a cutting-edge, and currently illegal, procedure called mitochondrial donation, a form of IVF which would allow those with the condition to have children, safe in the knowledge they would not be passing it on. Mito has taken everything from me, she says. If I die, at least James will still have a part of me. I would like him to look at our child, and say, You have your mums smile or your mums eyes.

An IVF treatment known as mitochondrial donation could potentially save up to 60 Australian children a year from being born with the condition. Credit:

Mitochondrial donation has been labelled immoral and unethical, a slippery slope to designer babies, not to mention potentially unsafe. The only country in the world to have legalised it is the UK. A report by medical experts into the technologys potential application in Australia is due to be delivered to Health Minister Greg Hunt this month.

This fight is really personal to me, Beverley says. Short of a cure, people with mito should at least have the option of having healthy children.

Mitochondria are microscopic structures in human cells that provide the body with energy. For this reason, they are often described as the cells powerhouse. They are crucially important: if your mitochondria fail or mutate, your body will be starved of energy, causing multiple organ failure and premature death.

A stylised representation of a mitochondrion, which provides the body with energy. Malfunction can lead to organ failure and death.Credit:Josh Robenstone

Mito, which is maternally inherited, usually affects the muscles and major organs such as the brain, heart, liver, inner ears, and eyes. But it can cause any symptom in any organ, at any age. Indeed, the term mito includes more than 200 disorders, the symptoms of which are maddeningly varied and seemingly unrelated, leading to delayed diagnoses or incorrect diagnoses or, indeed, no diagnosis.

Many of these people have been fobbed off by doctors or laughed off by people who think they are hypochondriacs, says Dr David Thorburn, a mitochondrial researcher at the Murdoch Childrens Research Institute, in Melbourne, who has diagnosed some 700 cases over the past 28 years. Most people are relieved to finally know what it is, because that is the end of that part of their journey.

Its sometimes said babies produced as a result of mitochondrial donation would have three parents the mother, the father, and the donor.

Up to two million people worldwide have some form of mito. - Others, like Beverley, who have a less severe type of the disease, will get adult onset, and can expect to become ill in their 30s, 40s or 50s.

According to Thorburn, One of the things that most dismays families with mito is the lack of control they have over passing the condition down to future generations of their family.

Remaining childless is one way to stop the condition from being passed down, as is adopting, but as Thorburn acknowledges, There is an innate desire in many individuals to have their own children. For these people, mito donation offers the very real prospect that the condition is eliminated from future generations.

Mitochondrial replacement is a highly specialised procedure, requiring a level of manual dexterity sufficient to manipulate a womans egg, which is roughly the width of a human hair. Within that egg is a nucleus, where a persons genes are located, and the cytoplasm, the jelly-like substance that surrounds it. Mitochondria are found in the cytoplasm.

Mitochondrial replacement involves taking a donor females healthy egg, removing its nucleus and replacing it with the nucleus of the woman affected by mitochondrial disease, but whose nucleus is healthy. The egg is then fertilised using her partners sperm. (Another option is to fertilise the egg first, and then swap the nucleus.) The resulting embryo is then implanted into the mother.

Researcher David Thorburn: "Mito donation offers the very real prospect that the condition is eliminated from future generations."Credit:Josh Robenstone

Since more than 99.9 per cent of our genes are found in the eggs nucleus, which remains unaffected, the procedure will have no impact on the childs height, hair colour or mannerisms. Despite that, its sometimes said that babies produced as a result of mitochondrial donation would have three parents the mother, the father, and the donor.

The technology has been tested in mice for more than 30 years, but only since 2009 has research been done on human embryos, mainly in the UK. Almost from the start, the research was subject to sensational headlines about scientists playing God, and the possibility of genetic engineering, with much of the hysteria being fuelled by anti-abortion groups. The Catholic Church described it as a further step in commodification of the human embryo and a failure to respect new individual human lives.

In 2012, the Human Genetics Alert, an independent watchdog group in London, wrote a paper comparing any baby produced with mitochondrial replacement to Frankensteins creation, since they would be produced by sticking together bits from many different bodies. According to the Conservative British MP Jacob Rees-Mogg, the procedure was not a cure for disease, it is the creating of a different person.

Regulators subjected the technology to four separate scientific reviews, together with rounds of ethical debate and community consultation. In 2015, the UK Parliament voted to legalise the technology for use in humans, on the proviso that it only be available to those women at high risk of passing on the disease. Since then, 13 couples in the UK have received the go-ahead to undergo the procedure.

Its unclear how many children, if any, have been born: the parents have asked that details not be published. Meanwhile, scientists like Thorburn wait eagerly for news of any developments. I know the UK researchers well and have asked several of them, and they are keeping completely quiet about it in respecting the families wishes, he says.

Loading

If there have been babies born in the UK using the procedure, they arent the first. In April 2016, a child was born using the technique in Mexico, to a Jordanian mother who carried a fatal mitochondrial condition known as Leigh syndrome. The doctor in charge, an American fertility specialist called Dr John Zhang, later admitted that he had gone to Mexico because the procedure is illegal in America. In Mexico, he admitted, There are no rules.

Even those who want mitochondrial donation legalised in Australia concede that much remains unknown about the procedure. Its long-term risks can only be understood through lifelong health check-ups, but this is impossible until any children conceived via this procedure become adults. Implications for subsequent generations also remain unclear.

No medical procedure is 100 per cent safe, says Sean Murray, CEO of the Mito Foundation. But we think we are at the stage now where the benefits of the technology are greater than the risks.

One of the issues around safety concerns the compatibility of the donors mitochondria with the recipients nuclear genes. A 2016 study in mice suggested that mismatched mitochondria affected their metabolism and shortened their lives. Another concern is known as carryover, whereby a tiny amount of mutant mitochondria is inevitably transferred from the affected mothers egg into the donor egg during the procedure.

Instead of it being wiped out, the mutation might then reappear in the descendants of any girls born as a result. For this reason, some people have proposed that the procedure be restricted to male embryos only, but this raises all kinds of ethical issues around selective breeding and sex selection.

Loading

Indeed, it often seems as if the term ethical minefield was coined especially with mitochondrial donation in mind.

My primary ethical concern has to do with the sanctity of human life, says Father Kevin McGovern, a Catholic priest and member of the National Health and Medical Research Councils Mitochondrial Donation Expert Working Committee.

If mitochondrial donation is permitted here, the technique most likely to be used is pronuclear transfer, which requires that both the donors egg and the affected mothers egg be fertilised. [This is to ensure that both eggs are at the same developmental stage.] But once the nucleus is removed from the donors fertilised egg, it is discarded. For people who believe that life begins at conception, this is akin to murder. You are creating two lives and destroying one for spare parts.

The Catholic Church has consistently opposed mitochondrial donation. In a Senate inquiry into the technology in 2018, Dr Bernadette Tobin, director of the Plunkett Centre for Ethics at the Australian Catholic University, suggested the process was intrinsically evil.

The inquiry also heard from Father Anthony Fisher, Catholic Archbishop of Sydney, who raised concerns about the moral right of the child to know how he or she was conceived the problem of what he called genealogical bewilderment and the donors right to remain anonymous. He also worried that women might effectively become egg vending machines: The availability of human ova is often assumed when people talk about reproductive technology as if they were somehow there in a cupboard to be used. In fact, it means women have to be used to obtain these eggs. They are extracted by invasive procedures that do carry some risk.

A report by medical experts into mitochondrial donation and its potential application in Australia is due to be delivered to Health Minister Greg Hunt this month. Credit:Alex Ellinghausen

Equally troubling for the Australian Catholic Bishops Conference, the peak national body for the churchs bishops, was the fact that mitochondrial donation involved conceiving babies not by marital intercourse [but by] a technical procedure.

Most of these concerns are redundant, argues the Mito Foundations Sean Murray. We already have a well defined regulatory framework for dealing with all this, he says. As far as the donors right to remain anonymous, we would defer to the appropriate federal or state and territory regulations that apply for sperm or egg donations. In regard to a kids right to know they had a mitochondrial donor, societally there seems to be a preference to inform kids. Its important for them to understand their genetic lineage.

Then theres the matter of consent. The parents can wrestle with the ethical issues and weigh up all the risks, but the only person who cant consent to the procedure is the unborn child. Well, says Murray, they cant consent to being born with mito, either.

The Mito Foundations Sean Murray: "In regard to a kids right to know they had a mitochondrial donor, societally there seems to be a preference to inform kids."Credit:Joshua Morris

Murray, 47, is one of the founding directors of the Mito Foundation, which was established in Sydney in 2009. Mito runs in my family, he says. My older brother, Peter, died of it in 2009 at 45, and my mum passed away in 2011, at 70. What people often dont understand is that even in families that have mito, each member can have different mutational loads basically, different amounts of bad mitochondria. Peter got a high load, but I didnt. Thats why Im still here.

A computer scientist by training, Murray now works full-time on the foundation. Much of his job involves travelling around the country, explaining mito to politicians, journalists and philanthropists, raising funds for research and, most crucially, advocating for a change to the laws.

Mitochondrial donation falls foul of two pieces of legislation: the Research Involving Human Embryos Act 2002, and the Prohibition of Human Cloning for Reproduction Act 2002. The laws prohibit the implantation of a human embryo that contains more than two peoples genetic material. The laws were subject to a mandatory review in 2010, but the then Labor government recommended they remain the same.

In 2013, the Mito Foundation urged the government to revisit its decision. Two years later, it began lobbying in earnest. What we tried to get across was that the science around mito donation has come a long way since 2010, says Murray. Also, the process that the UK went through to legalise it really reassured us that the procedure is safe and effective.

Loading

In the past five years, Murray and his colleagues have consulted with more than 100 MPs and senators. Only one of them, according to Murray, said I dont like this. They have also talked to dozens of industry experts, including academics and medical and research bodies, about the benefits of mitochondrial donation. Most of them get it straight away, he says. We are talking about a technique that will prevent the chance of having a morbidly ill child.

Now, a breakthrough appears imminent. In February 2019, Health Minister Greg Hunt asked the National Health and Medical Research Council to look into the matter, review the science and conduct public consultation. The NHMRC is due to hand its report to Hunt this month. The expectation among the mito community is that he will recommend the laws be changed. Any proposals would then need to be debated in Parliament, where issues around reproductive medicine have, in the past, been hotly contested.

Murray expects some opposition from more conservative MPs, but nothing like the rancour seen in the NSW Parliament during last years debate over legalising abortion. Shadow health minister Chris Bowen has, for his part, said that Labor will support changing the laws.

Mitochondrial sufferer Shelley Beverley at home in Tasmania. This fight is really personal to me. Credit:Peter Mathew

Whether this will help people like Shelley Beverley is unclear. If Hunt gives it the green light, it will take two years at least for mitochondrial donation to become available to prospective parents, given the time involved in drafting and passing legislation, establishing a regulatory regime and getting doctors up to speed with the technology.

This will probably be too late for Beverley. I really only have about a year left to give it a go, she tells me. After that, my symptoms may progress and biologically things get worse after 35. She says she would consider going to the UK for the treatment, but that at present they are not accepting international patients.

Loading

In the meantime, she watches TV, and reads a little, but not too much. (It puts me to sleep.) She gardens: she has a bed of huge white and pink roses out the back of her house, as a memorial to her mother and brother. And she eats. James cooks for me. He lets me choose the best meat and potatoes! Ive put on weight since I met him. She describes James as something close to an angel. He will listen to every problem I have or feeling I experience. He will always put me first.

Beverley started going out with James when she was 21, right around the time she first went deaf. I was so scared that he wouldnt like me as much. I remember calling him and saying I was scared he would leave me. But James is still here. Im very lucky to have him, she says. If I go, I want him to have a part of me.

To read more from Good Weekend magazine, visit our page at The Sydney Morning Herald, The Age and Brisbane Times.

Tim Elliott is a senior writer with Good Weekend.

Read the original:

How far should genetic engineering go to allow this couple to have a healthy baby? - Sydney Morning Herald

Genetically targeted chemical assembly of functional materials in living cells, tissues, and animals – Science Magazine

From genetics to material to behavior

Introducing new genes into an organism can endow new biochemical functions or change the patterns of existing functions, but extending these manipulations to structure at the tissue level is challenging. Combining genetic engineering and polymer chemistry, Liu et al. directly leveraged complex cellular architectures of living organisms to synthesize, fabricate, and assemble bioelectronic materials (see the Perspective by Otto and Schmidt). An engineered enzyme expressed in genetically targeted neurons synthesized conductive polymers in tissues of freely moving animals. These polymers enabled modulation of membrane properties in specific neuron populations and manipulation of behavior in living animals.

Science, this issue p. 1372; see also p. 1303

The structural and functional complexity of multicellular biological systems, such as the brain, are beyond the reach of human design or assembly capabilities. Cells in living organisms may be recruited to construct synthetic materials or structures if treated as anatomically defined compartments for specific chemistry, harnessing biology for the assembly of complex functional structures. By integrating engineered-enzyme targeting and polymer chemistry, we genetically instructed specific living neurons to guide chemical synthesis of electrically functional (conductive or insulating) polymers at the plasma membrane. Electrophysiological and behavioral analyses confirmed that rationally designed, genetically targeted assembly of functional polymers not only preserved neuronal viability but also achieved remodeling of membrane properties and modulated cell typespecific behaviors in freely moving animals. This approach may enable the creation of diverse, complex, and functional structures and materials within living systems.

More:

Genetically targeted chemical assembly of functional materials in living cells, tissues, and animals - Science Magazine

Timeline Shows 3 Paths To COVID-19 Treatment And Prevention (INFOGRAPHIC) – Forbes

In uncertain times, we are witnessing one of the greatest moments in the history of science.

A projected timeline for treatment and prevention of the novel coronavirus. Although we are living ... [+] through uncertain times, we are also witnessing one of the greatest moments in science history.

Scientists are breaking speed records in their race to develop treatments for the new coronavirus. Some are panning through old molecules hoping to find effective drugs. Others are applying the latest breakthroughs in synthetic biology to engineer sophisticated treatments and vaccines.

Ive previously talked about some synthetic biology companies are racing to create treatments. Others like Mammoth Biosciences are developing much-needed testing. Every day brings additional reports of the latest breakthroughs from around the world. But how can we make sense of all this information?

To provide a big-picture perspective, SynBioBeta and Leaps by Bayer have partnered to help visualize the overall progress of the research community. At the heart of the project is an infographic showing the timeline to the various treatments and preventions (click here to download it). Its based on data from The Milken Institute, which recently released a detailed tracker to monitor the progress of each of the more than 60 known COVID-19 treatments and preventions currently in development.

One takeaway: the progress to develop coronavirus treatments and preventions is moving at an unprecedented pace, with historic records being broken nearly every week.

The crisis response from the global biotech community has been truly inspiring, says Juergen Eckhardt, SVP and Head of Leaps by Bayer, a unit of Bayer AG that leads impact investments into solutions to some of todays biggest challenges in health and agriculture. We are excited to partner on this visual timeline to help a broader audience understand how and when scientific innovation may bring us through this deeply challenging time.

COVID19: Projected timeline for treatment and prevention. Three paths: pre-existing drugs, antibody ... [+] therapies, and vaccines.

There are standard stages to getting a drug approved. In Phase 1 trials, a drugs safety is assessed in a small group of healthy subjects. In later stages (Phase II & III), efficacy is measured in a larger number of people, often versus a placebo. The situation with COVID-19 is predicted to become so dire so quickly, however, that many are looking to fast-track testing. This could include granting experimental drugs expanded access, for compassionate use, which would allow physicians to give them to patients who are critically ill before testing is complete.

The fastest way to safely stop COVID-19 would be to discover that an already-approved medication works against it. Repurposed drugs do not require the same extensive testing as novel medicines and may already be available in large quantities. The Milken Institutes tracker identifies 7 candidate drugs in this category.

One is the malarial medicine chloroquine, which in recent days has been touted by some as a possible miracle drug against the coronavirus. German pharmaceutical company Bayer last week donated three million tablets of chloroquine to the U.S. The FDA and academics are together investigating whether it can provide relief to COVID-19 patients.

There are hundreds if not thousands of other FDA-approved drugs on the market that are already proven safe in humans and that may have treatment potential against COVID-19, so many scientists are rapidly screening the known drug arsenal in hopes of discovering an effective compound.

Antibodies are proteins that are a natural part of the human immune system. They work around the clock in blood to block viruses and more. The problem at the moment is that because the novel coronavirus (known as SARS-CoV-2) is new, no one has had time to develop antibodies against it.No one, that is, except those who have recovered from COVID-19.

Antibodies taken from those people could help patients who are still infected. Such patient-to-patient transfers can be performed without extensive testing or lengthy approval processes so long as standard protocols are followed. It is yet unknown whether this treatment option will work for COVID-19, nor whether there will be enough recovered donors to deal with the infection at scale.

To improve this process, companies like Vancouver, WA-based AbCellera are applying new biotechnologies.

AbCellera is using proprietary tools and machine learning to rapidly screen through millions of B cells from patients who recovered from COVID-19. B cells are responsible for producing antibodies. The company has announced a partnership with Eli Lilly on this project and aims to bring its hottest antibodies those that neutralize the virus to the clinic.

AbCellera's platform has delivered, with unprecedented speed, by far the world's largest panel of anti-SAR-CoV-2 antibodies," said Carl Hansen, Ph.D., CEO of AbCellera, in a statement. "In 11 days, we've discovered hundreds of antibodies against the SARS-CoV-2 virus responsible for the current outbreak, moved into functional testing with global experts in virology, and signed a co-development agreement with one of the world's leading biopharmaceutical companies. We're deeply impressed with the speed and agility of Lilly's response to this global challenge. Together, our teams are committed to delivering a countermeasure to stop the outbreak."

James Crowe at Vanderbilt University is also sifting through the blood of recovered patients. Using a new instrument called Beacon from a company called Berkeley Lights. Crowes team has been scouring through B cells to find antibodies that neutralize SARS-CoV-2. The technology behind this project was developed in recent years with funds from the Department of Defense.

Normally this would be a five year program, Crowe told me. But in the rapid process his team is following, animal studies could be done in as fast as two months.

This morning, Berkeley Lights announced a Global Emerging Pathogen Antibody Discovery Consortium (GEPAD) to attack COVID-19 and other viruses. It is partnering with Vanderbilt University, La Jolla Institute for Immunology, and Emory University to accelerate the work above to the broader research community.

This collaboration also included commercial partners, including Twist Bioscience, who synthesized DNA for the project.

Our mission is to provide the raw material needed for biologists to make breakthroughs, said Twists CEO Emily Leproust. If DNA is needed, we want to make it, quickly and perfectly

Another company that specializes in DNA synthesis, SGI-DNA, is offering its tools at much reduced cost to researchers developing COVID-19 treatments. The company said that people from around the world are coming to them for help.

"There is zero time to waste," said Todd R. Nelson, Ph.D., CEO of SGI-DNA. He said that researchers need synthetic DNA and RNA, which its Bio-XP machine can provide in as little as eight hours.

Nelson continued, "In a matter of a day or two, we have built the genes thought to be critical to the development of successful vaccines against SARS-CoV-2. SGI-DNA has made them available in the form of different genetic libraries, which researchers can use to find druggable targets in a matter of hours, dramatically accelerating the time to market for therapeutics and vaccines.

Beyond searching for antibodies in recovered patients, biotechnologists have other tricks up their sleeves.

One approach involves genetically engineering laboratory mice to mimic the human immune system. These animals can then be presented with the virus or parts of the virus and allowed to recover. The hope is that their B cells would then produce effective antibodies. Because this happens in a controlled setting, biologists can better understand and engineer the process.

A company called GenScript was pursuing this strategy as early as February 4, when police escorted 8 transgenic mice immunized with the 2019 nCoV antigen to research labs in China. In 12 hours, its researchers successfully found specific antibodies in the mice that could recognize the novel virus and potentially block it from binding to cells. In less than 24 hoursagain using Berkeley Lights new Beacon instrument for working with thousands of individual, live cellsGenScript completed a series of steps that would have taken three months using previous technology.

Yet another approach involves computational approaches and artificial intelligence. Firms like Distributed Bio are using computers to reengineer antibodies to better target SARS-CoV-2. The company is optimizing antibodies that are known to target SARS-CoV-1, the virus behind the 2003 outbreak of SARS.

We believe broadly neutralizing antibodies with engineered biophysical properties will become key weapons to win the war against all coronaviruses said Jake Glanville, CEO of Distributed Bio.

Vaccines work by simulating infection, which allows the body to mount its own defense against a virus. Effective vaccines take time to develop, and they can take even longer to test. But recent progress in biotechnology is again accelerating these efforts.

Notably, Moderna has launched a Phase 1 vaccine trial against COVID-19 in record time. Patients in Seattle have already begun receiving injections of an experimental mRNA vaccine. Moderna cranked out doses of this and won approval from the FDA for testing in just 44 days an all-time record.

These programs show a massive focus on a common enemy, and a coming together of disparate firms.

Ginkgo Bioworks, a giant in the emerging field of synthetic biology, has announced a $25 million fund to help spur even more collaboration. The company is offering its laboratory equipment and know-how to anyone with a good idea of how to stop COVID-19. We dont want any scientists to have to wait. The pandemic has already arrived, so the time for rapid prototyping and scale-up is right now, said Jason Kelly, CEO of Ginkgo.

These effortsand the infographic aboveshould give you hope. Although we are all now living in uncertain times, we are also witnessing one of the greatest moments in the history of science.

It's a terrible time, and simultaneously a fantastic time to see the global science community working together to conquer this very hard and challenging disease, said Berkeley Lights CEO Eric Hobbs. We are also learning and developing the tools and technologies to ensure that we can react faster to the next threat, so that we don't get to this point again in the future.

Follow me on twitter at @johncumbers and @synbiobeta. Subscribe to my weekly newsletters in synthetic biology.

Thank you to Ian Haydon and Kevin Costa for additional research and reporting in this article. Im the founder of SynBioBeta, and some of the companies that I write aboutincluding Leaps by Bayer, Mammoth Biosciences, Distributed Bio, Twist Bioscience, SGI-DNA, Genscript, Berkeley Lights, and Ginkgo Bioworksare sponsors of the SynBioBeta conference and weekly digest heres the full list of SynBioBeta sponsors.

Here is the original post:

Timeline Shows 3 Paths To COVID-19 Treatment And Prevention (INFOGRAPHIC) - Forbes

After Coronavirus the World Will Never Be the Same. But Maybe, It Can Be Better – Singularity Hub

Life has changed a lot in the past few days, weeks, or months, depending where you live. As efforts to contain the novel coronavirus ramp up, its likely going to change even more. But were already sick of being at home all the time, we miss our friends and families, everythings been canceled, the economy is tanking, and we feel anxious and scared about whats ahead.

We just want this to be over, and we figure its only a matter of time. Were making plans for what well do when things go back to normaland banking on that happening.

But what if life never fully goes back to how it was pre-coronavirus? What if this epidemic is a turning point, and after it the world is never the same?

More importantlyor, at least, more optimisticallywhat if the world could come out of this crisis better than it was before?

Jamie Metzl, technology and healthcare futurist, geopolitical expert, entrepreneur, author of Hacking Darwin: Genetic Engineering and the Future of Humanity, and Senior Fellow of the Atlantic Council, thinks this is possiblebut it all depends on what we do and how we behave right now. In a talk at Singularity Universitys virtual summit on COVID-19 last week, Metzl explained why he believes that were never going back to normaland what we should be doing now to make the new normal a good one.

For many of us, the most impactful geopolitical event thats happened during our lifetime was the terrorist attacks of September 11, 2001. The world changed that day, and its never returned to how it was before.

A flu-like pandemic with a relatively low mortality rate may seem minor compared to the deliberate murder of thousands of innocent people. But, Metzl said, Its my contention that this isnt a 2001 moment, this is something much bigger. I think of this as a 1941 moment.

1941 was the thick of World War II. Nobody knew what the outcome of the war was going to be, everybody was terrified, and the US and its allies were losing the war. But even in the height of those darkest of times, Metzl said, people began imagining what the future world would look.

It was 1941 when President Roosevelt gave his famous Four Freedoms speech, and when American and British leadership issued the Atlantic Charter, which set out their vision for the post-war international order. To this day, our lives exist within that order.

The situation were in right now is, of course, different; its not a war. It is, in Metzls words, a convergence of the worlds of science and biology and the world of geopolitics. And as the coronavirus crisis continues to play out, its geopolitical implications are going to become much greater.

Metzl shared a quote from Italian Communist theorist Antonio Gramsci, written in the 1930s: The old world is dying and the new world struggles to be born. Now is the time of monsters.

Oofthats a big statement.

Metzl deconstructed it. For starters, he said, the post-WWII order that weve all grown up with was dying before this virus appeared.

Post-WWII planners envisioned a world that shared sovereignty and curbed nationalism. But were now in a period of dramatic re-nationalization of the world, with populist, extremist, or authoritarian leaders in power from Brazil to the US to China, and many countries in between.

Institutions intended to foster global cooperation (like the World Bank, the International Monetary Fund, the United Nations, and the World Health Organization) have been starved in the context of this re-nationalization, and as a result we dont have effective structures in place to address global crisesand not just coronavirus. Think of climate change, protecting the oceans, preparing for a future of automation and AI; no country can independently take on or solve these massive challenges.

Not all is lost, though. There are some positive pieces of this globalization story that we also need to be mindful of, Metzl said.

When the Spanish flu pandemic hit in 1918, there were only 2 billion people on Earth, and of those 2 billion only 30 percent were literate.; the brain pool for solving problems was about 600 million people.

Now we have a global population of 7.5 billion and an 86 percent literacy rate, which means over 6.5 billion people can be part of the effort to fix whats broken. Just as crucially, were more connected to each other than weve ever been. It used to take thousands of years for knowledge to transfer; now it can fly across the world over the internet in minutes. The pandemic moves at the speed of globalization, but so does the response, Metzl said. The tools were bringing to this fight are greater than anything our ancestors could have possibly imagined.

But at the same time were experiencing this incredible bottom-up energy and connectivity, were also experiencing an abysmal failure of our top-down institutions.

Have you felt afraid these last few days and weeks? I sure have. The economy is tanking, people are losing their jobs, people are getting sick, and we dont know the way out or how how long its going to last. In the meantime, a lot of unexpected things will happen.

There will be an economic slowdown or recession, and there will be issues with our healthcare systemsand these are just the predictable things. Metzl believes well also see significant second and third-order effects. If the poorer parts of the world get hit hard by the virus, we may see fragile states collapsing, and multi-lateral states like the European Union unable to support the strain. Our democracies are going to be challenged, and there may be soft coups even here in the US, Metzl said. Speaking of challenges to democracy, there are actors whose desires and aspirations are very different from our own, and this could be a moment of opportunity for them.

The world is not going to snap back to being exactly like it was before this crisis happened, Metzl said. Were going to come out of this into a different world.

We dont know exactly what that world will look like, but we can imagine some of it. Basically, take the trends that were already in motion and hit the fast-forward button. Virtualization of events, activities, and interactions. Automation of processes and services. Political and economic decentralization.

But for the pieces of the future that were unsure of, now is 1941. Now is the time when we need to think about what we would like the new world to look like, and start planning for it and building it, Metzl said.

In hindsight, its easy to picture a far better response and outcome to the COVID-19 outbreak. What if, three months ago, thered been a global surveillance system in place, and at the first signs of the outbreak, an international emergency team led by the World Health Organization had immediately gone to Wuhan?

Weall of usneed to re-invigorate a global system that can engage people inclusively across differences and across countries, Metzl said. We need to be articulating our long-term vision now so that we can evaluate everything against that standard.

Theres not a total lack of a positive long-term vision now; the UN sustainable development goals, for example, call for gender equality, no poverty, no hunger, decent work, climate action, and justice (among other goals) around the world.

The problem is that we dont have institutions meaningful enough or strong enough to effect realization of these principles; theres a mismatch between the global nature of the problems were facing and the structure of national politics.

Just as our old normal was the new normal for our grandparents in the mid-1900s, this new normal that feels so shocking to us right now will simply be normal for our children and grandchildren. But there are some criticaland wonderfuldifferences between the mid-1900s and now.

We have more educated people, stronger connections, faster sharing of information, and more technological tools and scientific knowledge than ever before in history. The number of people who can be part of this conversation is unprecedented, Metzl said. We couldnt have done this in the industrial age or even the nuclear age. Theres never been this kind of motivation combined with this capacity around the world.

In 1941, the global planning process was top-down: a small group of powerful, smart people decided how things would be then took steps to make their vision a reality. But this time will be different; to succeed, the new global plan will need to have meaningful drive from the bottom up.

We need to recognize a new locus of power, Metzl said. And its us. Nobody is going to solve this for us. This is our moment to really come together.

Image Credit: Joseph Redfield Nino from Pixabay

Original post:

After Coronavirus the World Will Never Be the Same. But Maybe, It Can Be Better - Singularity Hub

COVID 19: 21st Century Reality Check – The Globalist

The impact of COVID 19 is far-reaching and profound. The virus is unseen and moving fast. It can infect without symptoms. Its use of innocent carriers makes everyone suspect.

It also attacks in a random fashion, with just enough victims to easily lead the rest to the edge of panic. And while COVID 19 appears to kill 20 to 30 times more people than the worst form of flu, it seems to still be like a common cold, in that it may not be strong enough for the body to develop a lasting immune system response.

In spite of the earlier hype, artificial intelligence (AI) has singularly failed to help much.

There was little in the way of predictive analytics about where the pandemic would strike and how it would develop.

The jury is also out on another much-touted darling, biotechnology. Biotech has yet to offer anything like a silver bullet.

Meanwhile, the entire world waits with baited breath for a designer drug or vaccine spliced and stitched up with genetic engineering tools like CRISPR, to vanquish COVID 19.

At the present stage, we cant even answer very simple questions: What comes when this current peak wanes?

All we seem to know is that there will be a new normal. For the foreseeable future, it may not be like anything before.

There is even a good chance some of the same questions we now face may still be around during the next peak of infections, and the one after.

Amidst all this hand-wringing and unleashing of previously unseen economic rescue packages, only the Anglo-Saxons and the Calvinist Dutch have asked the Mother of all Questions:

Who is prepared to pay the price for an abnormal, new normal ? And what exactly will this look like?

The first victim of COVID 19 is likely to be tourism. Which matters because it is one of the worlds biggest economic sectors.

The era of retirement voyages on cruise ships is probably sunk for good. But what about airlines, the lifeblood of the 21st centurys globalized economy?

After all, this is an industry where passengers are even far more densely packed than on cruise ships, sitting squeezed together for hours on end in an air-tight tube.

Worse, owing to the industrys mantra of operating a hub-and-spokes system at airports, a single asymptomatic carrier may be enough to kindle a burgeoning cycle of infections in many different countries.

That evidently is what happened at resorts in Austria and Italy during that fateful ski holiday week at the end of February.

Note as well that, in 2003 when COVID 19s SARS cousin sprouted in China, 1.65 billion people travelled by air that year. In 2018, the figure was already two-and-a-half times higher, at 4.2 billion.

Moving up and down the economic value chain produces only more of the same uncomfortable questions.

Here are some of the pertinent questions to be asked:

1. What is the business outlook for AirBnB, co-living, bars and cafes, discos and cinemas, open-air markets?

2. Will remote learning be the death knell for brick-and-mortar university campuses?

3. How virus-proofed are food and fruit supply chains from Spain to northern Europe, from Mexico to the United States?

4. Do the lorries backed up at borders within the Schengen area conceal refugees?

5. At a time when emergency services are stretched, what is the chance of a terror attack, and how effective would be a response?

6. And although it is clear that a lockdown reduces most targets for a mass casualty attack, there is one notable exception the public hospital.

Most of the world remains hopeful about vaccination against COVID 19. However, a successful vaccine is unlikely to be ready before the end of this year.

After this, there will be the challenge of ramping up production and organizing the immunization of billions of people.

In the meanwhile, should one or more pharmacological treatments be successful, the question remains: How many can be treated, and where?

With 5-10% of COVID 19 cases needing ventilator support, is there room for drive-in halfway houses, between home and hospital, or hospital and intensive care?

In many parts of Europe, serious debate about such questions have been derailed by newsbytes and occasional self-congratulation about hospitals and ICUs.

Way beyond this, tough questions need to be faced. One of the most immediate issues is strategic self-sufficiency.

Take the case of Germany, the presumed master of infrastructure spending and planning. With war out of fashion in Europe, little attention was given to the amazing finding that a large part of Germanys fighter jets, helicopters, tanks and submarines did not work when tested.

This was largely an ideological battle between the left and the political center. However, public health should be another matter.

Nobody is really surprised that there was a severe shortage of face masks even in hospitals in Italy. But why on earth is there one in Germany?

Health systems in ageing societies may lack nurses and lab technicians but face masks?

Just how off we are on our presumably modern reaction and thought patterns, consider this: Before the COVID 19 crisis, the world was obsessed about plastics, of doing away with them.

As is ironically turns out now, the best defense against viral contamination is a plastic barrier. All of a sudden everybody prays for plastics Great Return.

Amidst the many ethics questions we will have to ponder, there are two lessons which COVID 19 might teach us.

1. To pay for the panoply of ever-cheaper products we do not really need, we have lived our lives on a curve of diminishing returns. There will be a recession, probably a severe one, but the world economy will recover. To what degree is our choice.

2. As we sit locked down at home, we can celebrate the return of time. We do not need to overwork to save for free time, at a later date.

It may also be salutary to remember that refugees did not cause the 21st centurys first pandemic. Tourists did.

Read the original:

COVID 19: 21st Century Reality Check - The Globalist

If and when it has time, the UK must ponder its post-Brexit biotech options – just-food.com

Johnson has championed deregulation and divergence from the EU on GM

In the three years after the UK's referendum on EU membership, it was often said Brexit had monopolised the political agenda leaving precious little "bandwidth" for anything else. But who would have imagined an issue of such magnitude was about to emerge that would consign Brexit to the "and in other news" section of TV bulletins?

That the biggest Brexit story last week was that EU negotiator Michel Barnier had tested positive for coronavirus and David Frost, his UK counterpart, is self-isolating after showing symptoms, tells its own story.

A few critical and challenging issues had dominated the long debates over the UK's membership of the EU, while undeniably important topics, including the country's differences with Brussels over genetic modification and biotechnology, were relatively little discussed. However, UK prime minister Boris Johnson is going some way to correcting that.

Boris backs British biotech

Since securing his premiership and withdrawal from the EU, Johnson has repeatedly made a point of championing deregulation and divergence from the EU on GM as a Brexit boon for the UK and a priority for his administration. Johnson also appointed George Eustice, a longstanding and vocal critic of the EU approach, as Secretary of State at the Department for the Environment, Food and Rural Affairs (Defra).

Based rigidly on the precautionary principle, EU regulations both on planting GM crops and commercialising foods made from GMO ingredients are consideredby many scientists overly restrictive and lengthy. Over the years, governments and policymakers from across the political divide have sympathised with that view but could do no more than push for reform in Brussels.

Johnson now has the opportunity to put the UK on a different footing. His intended direction of travel is clear, though GM is a highly contentious issue that could challenge even his libertarian instincts.

There has been strong support for deregulation on biotech in the scientific community for many years, so Johnson's remarks have been welcomed enthusiastically by crop scientists.

Professor Jonathan Jones of The Sainsbury Laboratory crop research institute, a practitioner and energetic proponent of GM technology for three decades, bemoans the "glacial" progress of GM regulation, but says the Johnson rhetoric is "exciting".

However, he cautions: "Of course, he's not delivered everything he's promised in the past but I think he's serious on this one. How rapidly we get there from here I don't know. It's complicated."

Consumer fears easily provoked

A prime challenge is the consumer concern and suspicion GM has always attracted. This has engendered a highly cautionary approach by retailers, as reflected in a comment from Andrew Opie, director of food and sustainability at UK food retail trade body The British Retail Consortium, for this article. "Retailers do not currently sell genetically-modified food under their own brands and would not do so unless there is a change in consumer demand," Opie says.

"Activist groups often behave irresponsibly in terms of inflaming public fears about something that is totally benign"

Others would say consumer fears which, while borne partly out of the understandable natural caution people have about technology related to food, are stoked by misinformation and sensationalised reporting, resulting in the retailers' and public policy being led by the least well informed on the topic. "Activist groups often behave irresponsibly in terms of inflaming public fears about something that is totally benign," Prof. Jones contends.

Food manufacturers have also been somewhat reticent about supporting GM publicly, even if they recognise the benefits of the technology.

Asked by just-food for its view on where the UK should go on biotech, the UK food manufacturing representative body The Food and Drink Federation, states: "FDF believes that modern biotechnology, including genetic modificationand new breeding techniques, offers considerable potential to improve the quality and quantity of [the] food supply and could contribute to sustainability by helping to produce more food using fewer resources and with less impact on the environment. FDF recognises that the impact of biotechnology must be objectively assessed, based on sound science and evidence, and be underpinned by an effective regulatory landscape."

The recognition of the potential benefits but a reluctance to go into battle on behalf of GM can clearly be seen in that statement. While Prof. Jones brands current policies on GM as the "tyranny of the more risk-averse", he says he "totally understands the brand reputation pressures both manufacturers and retailers are under". They see "a little bit of upside in terms of cost reduction but a vast amount of downside in terms of risking damage to my precious brand".

All this means biotech has been somewhat friendless, not receiving the widespread support from the private sector that technological innovation in other fields often can. Its backing by "Big Agri" has obviously been significant globally but the associations within that sector help foster some of the distrust, giving environmental campaigners a potent focus for their activities that has resonated with the public.

Farmer support

The National Farmers Union has generally been more publicly supportive of GM, however. Helen Ferrier, chief science and regulatory affairs adviser at the NFU, says it supports a "proportionate and enabling" regulatory framework on GM.

Vicki Hird of food and environment pressure group Sustain, however, suggests the picture is more mixed. "There's a lot of farmers I know who aren't members of the NFU [who] have a position on GM and biotech which is quite different from the NFU," Hird says, adding that protection of their European market will be a prime concern for many, underlining the influence ongoing negotiations could have on the UK's biotech ambitions.

"The UK currently remains aligned with the EU in its approach to genetically modified food. The UK's stance beyond January 2021 will depend very much on the outcome of trade negotiations," the BRC's Opie says.

Gene-editing move?

Where there could be more immediate progress is in the field of new gene-editing techniques. Dr Richard Harrison, director of Cambridge Crop Research, part of the National Institute of Agricultural Botany (NIAB), is leading research utilising modern gene-editing techniques, including CRISPR-Cas9, to modify the genetic make-up of the Fusarium venenatum fungus, the mycoprotein source for meat substitute brand Quorn, owned by Philippines group Monde Nissin.

"We're trying to understand how the fungus uses different carbon sources, and also how it regulates responses to nitrogen as well, because if we could understand that, then we'd be able to use a far greater range of crop-based carbon sources to produce mycoprotein," Harrison explains.

Being able to vary what mycoprotein is fed on could broaden the options for how and where mycoprotein can be sustainably produced as a meat alternative. The research is funded by the Biotechnology and Biological Sciences Research Council, with Quorn manufacturer Quorn Foods, a subsidiary of Monde Nissin,as a project partner and co-funder.

However, Harrison stresses the objective is not to produce a genetically engineered Fusarium venenatum that Marlow Foods might then commercialise, but that the gene-editing techniques are being used as "a research tool to validate our hypotheses".

Speaking to just-food last year, then Quorn Foods CEO Kevin Brennan said the company would "never go anywhere near genetic modification". This is not surprising and is common position among food companies. Owing to a 2018 European Court of Justice ruling, any food produced from ingredients derived from the gene-editing processes Harrison's team is employing would be subject to the EU's GM regulations and would have to be labelled as containing GMOs.

Brennan said the research "provides underpinning science for alternative carbohydrates but also to support feed optimisation". He continued: "If we can understand at a granular level what the organism reacts to we can optimise feedstock to encourage the ideal growth".

Ironically, some older and less accurate mutagenesis techniques, such as using gamma radiation and chemicals to alter genetic profile, fall outside the EU regulation. "All scientists are asking for is an objective evaluation rather than emotive one," Harrison adds.

In common with many scientists, Harrison believes EU regulations on genetic modification and gene editing to be overly restrictive and an impediment to scientific progress, not least as it discourages private-sector investment. So, would there be greater commercial opportunities for food companies, and consequently more investment in research, if the UK were to diverge from EU biotech regulations?

"Would a more proportionate regulatory framework bring in more investment? I think the answer is yes"

Harrison has no doubt there would, and Prof. Jones concurs. "Would a more proportionate regulatory framework bring in more investment? I think the answer is yes."

The NFU's Ferrier also believes regulatory reform will boost investment. "What we're interested in as an organisation is that you're able to move from the research into private-sector R&D and then commercialisation, because as long as seed companies don't see the EU and the UK as somewhere that they want to invest in, then you can do as much brilliant science as you like but the UK, farmers, society, environment, won't get any of the benefit because it will just stay in the research community."

Climate emergency

With regard to the regulation of genetic technologies in food production overall, Harrison urges a strictly evidence-led approach, not least given the challenges posed by climate change.

"There is enormous potential to grow crops with fewer pesticides by using naturally-occurring, disease-resistance genes. You could do that through traditional breeding but that takes a long time and costs a lot of money. Genetic technology makes it a lot faster and we should really have access in the 21st century to those technologies because we rapidly need to reduce our greenhouse gas emissions. Genetic technology could really be a powerful tool to accelerate our decarbonisation of the foodchain."

Prof. Jones adds: "We need every tool in the toolbox to address the perfect storm of rising temperatures, greenhouse gas emissions and rising population."

While recognising the benefits of separating gene-editing technology from GM, Prof. Jones is concerned arguing in favour of this may unintentionally lend weight to the view that there is still something to be feared in genetic engineering. "There are literally dozens of technologies like that that would be fantastic for the sustainability of agriculture, that you can only really accomplish by moving genes from one plant to another or by moving genes between bacteria and plants which is something that's happened naturally in evolution scores of times," he says, strongly urging the government to follow through on its supportive stance on GM.

Nevertheless, gene editing could be the more immediate movethat is easier to negotiate politically and practically. It is also almost impossible to imagine the UK moving out of the transition period with an ECJ ruling featuring in its legislation. Ferrier believes the UK could also work with other member states, many of which were concerned by the ECJ ruling, to move EU opinion on the issue. "This is the opportunity to work with other member states who are similarly concerned about it. That is an area that the UK research sector can have a strength in and it is a really exciting area for developing products that farmers could grow."

While the UK government is so far holding to its December deadline, the coronavirus pandemic seems highly likely to result in the extension of the transition period. When it does finally leave the EU, the UK is likely, at the very least, to have a different regulatory approach to gene editing, if not immediately on GM overall.

When exactly the transition period will now end, however, may depend more on how successful scientists have been at understanding the genome of Covid-19 than the genetic composition of any food crop.

Continue reading here:

If and when it has time, the UK must ponder its post-Brexit biotech options - just-food.com

Covid 19: HOMEF Cautions On Use of Biodiversity – Leadership Newspaper

The Director, Health of Mother Earth Foundation, Dr Nnimo Bassey has called for sober consideration on the development and use of Biodiversity following the virtual shut down of global economy.

Dr Bassey gave the charge in his welcome remarks at a stakeholders conference which held in Abuja on Monday, March 23, 2020 with the theme Agricultural Technofixes and the state of Biosafety in Nigeria.

In his words The world is virtually shut down due to the ravages of a virus. This is no time for grandstanding or for anyone to claim that they have got anything under control.

He said addressing the issues of agricultural technofixes and the state of our Biosafety gives us the template to consider the current situation in our world and the unpredictability of what could happen next. Noting that while scenario planners may have foreseen a pandemic of the scale that Corona virus has provoked, it comes as a total surprise to the average person.

The Activist emphasised that they had had on several occasions warned that things could go deeply wrong and out of hands if humans persist in toying with the genetic make up of living organisms for the consideration of power in a few moguls and for profit, adding that when humans engineer crops to make them act as pesticides, nature offers super pest or super bugs.

In any case humans get trapped in needless and unwinnable battles against nature he said

Recently, mainstream genetic engineering has progressed to the level of editing genetic makeup of organisms and not necessarily having to engage in trans-species transfer of genetic materials.This has focussed on becoming extinction technologies

He maintained that while modern biotechnology promoters like the National Biotechnology Development Agency (NABDA) and the regulatory National Biosafety Management Agency(NBMA) feel confident that they can handle any sort of technicalities in both the mainstream and newfields of extreme technofixes We are deeply concerned that their grandstanding would not stop the purveyors of these technologies from weaponising them.

Giving the opening remarks, Minister of state for Environment, Barrister Sharon Ikeazor, stated that, With Nigerias population projected to exceed 400 million by 2050, an immediate priority for agricultural is to maximize crop productivity in a manner that is environmentally friendly, sustainable and cost effective.

The Minister who was represented by the Director General/CEO, National Biosafety Management Agency (NBMA), Dr. Rufus Ebegba said Government efforts to ensure food security have been challenged by climate change effects such as droughts and floods, erratic weather conditions and declining soil fertility among others.

The Minister said to address these challenges, Nigeria has adopted several technologies including modern agricultural biotechnology to ensure food security in the country.

She maintained that to protect biological diversity from the potential risks posed by products arising from modern biotechnology such as Genetically Modified Organisms (GMOs) and ensure international best practices in the application of modern biotechnology, Nigeria has put in place the necessary legal and policy instruments to guide its development and safe use.

The Minister however noted that Biodiversity in Nigeria is under enormous pressure and highly threatened due to land use changes from agriculture and over grazing,over exploitation of natural resources, environmental pollution and climate change.

Like Loading...

Read this article:

Covid 19: HOMEF Cautions On Use of Biodiversity - Leadership Newspaper

2020-2025 Global and Regional Genetic Engineering Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report…

The global Genetic Engineering market report by HNY Research offers users a detailed overview of the market and all the main factors affecting the market. The study on global Genetic Engineering market, offers profound understandings about the Genetic Engineering market covering all the essential aspects like revenue growth, supply chain, sales, key players and regions. There is a target set in market that every marketing strategy has to reach. This report on Genetic Engineering focusses on different categories that define this market with a systematic approach that addresses the consumer base, researchers and market experts like the stakeholders. It also gives a clear perspective towards the competition and demand and supply chain.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4360374

Manufacturer Detail

By Market Players:Thermo Fisher Scientific Inc., GenScript, Amgen Inc., Genentech, Inc., Merck KGaA, Horizon Discovery Group plc, Sangamo Therapeutics, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc.

By Application

By TypeArtificial Selection, Cloning, Gene Splicing, Others

The Genetic Engineering market report also offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the global Genetic Engineering market. This report on Genetic Engineering has been very well drafted to benefit anyone studying it. There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. Every market research report follows a robust methodology to define its market value. By doing so, the Genetic Engineering research study by HNY Research offers collection of information and analysis for each facet of the Genetic Engineering market such as technology, regional markets, applications, and types.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-intraductal-papilloma-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

This study can benefit investors and business owners in many ways. It studies the business models, strategies, growth, innovations and every information about manufacturers that can help make business predictions and fetch good results. Making right business decisions is an undeniable measure that needs to be taken for market growth. Every market has a set of manufacturers, vendors and consumers that define that market and their every move and achievements becomes a subject of studying for market researchers and other stakeholders. One of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Genetic Engineering report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. Another important aspect of every market research report by HNY Research is the study of the key players or manufacturers driving the market forward. The process helps to analyze the opponent thoroughly.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4360374

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us: Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

View original post here:

2020-2025 Global and Regional Genetic Engineering Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report...

Genetic engineering company says they have created a coronavirus vaccine – 9News.com KUSA

HOUSTON A Houston-based genetic engineering company said it has a vaccine aimed at the deadly coronavirus outbreak, according to a report by the Houston Business Journal.

The genetic engineering firm, Greffex Inc. has one of its laboratories based in Aurora, Colorado.

RELATED: Coronavirus death toll hits 2,100 in mainland China

RELATED: Colorado man living in China posts brutally honest Instagram videos of coronavirus self-quarantine

John Price, president and CEO of Greffex Inc., told KHOU, our sister station in Houston, that Greffex's scientists completed the coronavirus vaccine this week.

The trick in making a vaccine is can you scale the vaccine that youve made to be able to make a certain number of doses, can you test the vaccine quickly and efficiently and then can you get it into patients and thats where we have an edge as well on the other companies that are out there," said Price. "And that has to do with speed and essential uniformity of how we make vaccines, so that drops the cost down.

Price said the vaccine will now move into a testing phase with the Food and Drug Administration.

The Houston Business Journal reported, in September 2019 Greffex received an $18.9 million contract from the National Institute of Health's National Institute for Allergy and Infectious Diseases to develop new treatments for infectious threats.

If the vaccine gets government approval, Price said his company plans to give it away for free to nations hit hard by the coronavirus outbreak.

SUGGESTED VIDEOS | Local stories from 9NEWS

Link:

Genetic engineering company says they have created a coronavirus vaccine - 9News.com KUSA

Building a ‘doomsday vault’ to save the kangaroo and koala from extinction – CNET

The road into Batlow is littered with the dead.

In the smoky, gray haze of the morning, it's hard to make out exactly what Matt Roberts' camera is capturing. Roberts, a photojournalist with the Australian Broadcasting Corporation, keeps his lens focused on the road as he rolls into the fire-ravaged town 55 miles west of Canberra, Australia's capital. At the asphalt's edge, blackened livestock carcasses lie motionless.

The grim scene, widely shared on social media, is emblematic of the impact the 2019-20 bushfire season has had on Australia's animal life. Some estimates suggest "many, many billions" of animals have been killed, populations of endemic insects could be crippled and, as ash washes into riverways, marine life will be severely impacted. The scale of the bushfires is so massive, scientists are unlikely to know the impact on wildlife for many years.

But even before bushfires roared across the country, Australia's unique native animals were in a dire fight for survival. Habitat destruction, invasive species, hunting and climate change have conspired against them. Populations of native fauna are plummeting or disappearing altogether, leaving Australia with an unenviable record: It has the highest rate of mammal extinctions in the world.

A large share of Australia's extinctions have involved marsupials -- the class of mammals that includes the nation's iconic kangaroos, wallabies, koalas and wombats. A century ago, the Tasmanian tiger still padded quietly through Australia's forests. The desert rat-kangaroo hopped across the clay pans of the outback, sheltering from the sun in dug-out nests.

Now they're gone.

Australia's 2019-20 bushfire season has been devastating for wildlife.

In a search for answers to the extinction crisis, researchers are turning to one lesser-known species, small enough to fit in the palm of your hand: the fat-tailed dunnart. The carnivorous mouse-like marsupial, no bigger than a golf ball and about as heavy as a toothbrush, has a tiny snout, dark, bulbous eyes and, unsurprisingly, a fat tail. It's Baby Yoda levels of adorable -- and it may be just as influential.

Mapping the dunnart's genome could help this little animal become the marsupial equivalent of the lab mouse -- a model organism scientists use to better understand biological processes, manipulate genes and test new approaches to treating disease. The ambitious project, driven by marsupial geneticist Andrew Pask and his team at the University of Melbourne over the last two years, will see scientists take advantage of incredible feats of genetic engineering, reprogramming cells at will.

It could even aid the creation of a frozen Noah's Ark of samples: a doomsday vault of marsupial cells, suspended in time, to preserve genetic diversity and help prevent further decline, bringing species back from the brink of extinction.

If that sounds far-fetched, it isn't. In fact, it's already happening.

Creating a reliable marsupial model organism is a long-held dream for Australian geneticists, stretching back to research pioneered by famed statistician Ronald Fisher in the mid-20th century. To understand why the model is so important, we need to look at the lab mouse, a staple of science laboratories for centuries.

"A lot of what we know about how genes work, and how genes work with each other, comes from the mouse," says Jenny Graves, a geneticist at La Trobe University in Victoria, Australia, who has worked with marsupials for five decades.

The mouse is an indispensable model organism that shares many genetic similarities with humans. It has been key in understanding basic human biology, testing new medicines and unraveling the mysteries of how our brains work. Mice form such a critical part of the scientific endeavor because they breed quickly, have large litters, and are cheap to house, feed and maintain.

The lab mouse has been indispensable in understanding physiology, biology and genetics.

In the 1970s, scientists developed a method to insert new genes into mice. After a decade of refinement, these genetically modified mice (known as "transgenic mice") provided novel ways to study how genes function. You could add a gene, turning its expression up to 11, or delete a gene entirely, shutting it off. Scientists had a powerful tool to discover which genes performed the critical work in reproduction, development and maturation.

The same capability does not exist for marsupials. "At the moment, we don't have any way of manipulating genes in a devil or a kangaroo or a possum," says Graves. Without this capability, it's difficult to answer more pointed questions about marsupial genes and how they compare with mammal genes, like those of mice and humans.

So far, two marsupial species -- the Tammar wallaby and the American opossum -- have been front and center of research efforts to create a reliable model organism, but they both pose problems. The wallaby breeds slowly, with only one baby every 18 months, and it requires vast swaths of land to maintain.

The short-tailed opossum might prove an even more complicated case. Pask, the marsupial geneticist, says the small South American marsupial is prone to eating its young, and breeding requires researchers to sift through hours of video footage, looking for who impregnated whom. Pask also makes a patriotic jab ("they're American so we don't like them") and says their differences from Australian marsupials make them less useful for the problems Australian species face.

But the dunnart boasts all the features that make the mouse such an attractive organism for study: It is small and easy to house, breeds well in captivity and has large litters.

"Our little guys are just like having a mouse basically, except they have a pouch," Pask says.

Pask (front) and Frankenberg inspect some of their dunnarts at the University of Melbourne.

A stern warning precedes my first meeting with Pask's colony of fat-tailed dunnarts.

"It smells like shit," he says. "They shit everywhere."

I quickly discover he's right. Upon entering the colony's dwellings on the third floor of the University of Melbourne's utilitarian BioSciences building, you're punched in the face by a musty, fecal smell.

Pask, a laid-back researcher whose face is almost permanently fixed with a smile, and one of his colleagues, researcher Stephen Frankenberg, appear unfazed by the odor. They've adapted to it. Inside the small room that houses the colony, storage-box-cages are stacked three shelves high. They're filled with upturned egg cartons and empty buckets, which work as makeshift nests for the critters to hide in.

Andrew Pask

Frankenberg reaches in without hesitation and plucks one from a cage -- nameless but numbered "29" -- and it hides in his enclosed fist before peeking out of the gap between his thumb and forefinger, snout pulsing. As I watch Frankenberg cradle it, the dunnart seems curious, and Pask warns me it's more than agile enough to manufacture a great escape.

In the wild, fat-tailed dunnarts are just as inquisitive and fleet-footed. Their range extends across most of southern and central Australia, and the most recent assessment of their population numbers shows they aren't suffering population declines in the same way many of Australia's bigger marsupial species are.

Move over, Baby Yoda.

As I watch 29 scamper up Frankenberg's arm, the physical similarities between it and a mouse are obvious. Pask explains that the dunnart's DNA is much more closely related to the Tasmanian devil, an endangered cat-sized carnivore native to Australia, than the mouse. But from a research perspective, Pask notes the similarities between mouse and dunnart run deep -- and that's why it's such an important critter.

"The dunnart is going to be our marsupial workhorse like the mouse is for placental mammals," Pask says.

For that to happen, Pask's team has to perfect an incredible feat of genetic engineering: They have to learn how to reprogram its cells.

To do so, they collect skin cells from the dunnart's ear or footpad and drop them in a flask where scientists can introduce new genes into the skin cell. The introduced genes are able to trick the adult cell, convincing it to become a "younger," specialized cell with almost unlimited potential.

The reprogrammed cells are known as "induced pluripotent stem cells," or iPS cells, and since Japanese scientists unraveled how to perform this incredible feat in 2006, they have proven to be indispensable for researchers because they can become any cell in the body.

"You can grow them in culture and put different sorts of differentiation factors on them and see if they can turn into nerve cells, muscle cells, brain cells, blood vessels," Pask explains. That means these special cells could even be programmed to become a sperm or an egg, in turn allowing embryos to be made.

Implanting the embryo in a surrogate mother could create a whole animal.

It took about 15 minutes to get this dunnart to sit still.

Although such a technological leap has been made in mice, it's still a long way from fruition for marsupials. At present, only the Tasmanian devil has had iPS cells created from skin, and no sperm or egg cells were produced.

Pask's team has been able to dupe the dunnart's cells into reverting to stem cells -- and they've even made some slight genetic tweaks in the lab. But that's just the first step.

He believes there are likely to be small differences between species, but if the methodology remains consistent and reproducible in other marsupials, scientists could begin to create iPS cells from Australia's array of unique fauna. They could even sample skin cells from wild marsupials and reprogram those.

Doing so would be indispensable in the creation of a biobank, where the cells would be frozen down to -196 degrees Celsius (-273F) and stored until they're needed. It would act as a safeguard -- a backup copy of genetic material that could, in some distant future, be used to bring species back from the edge of oblivion, helping repopulate them and restoring their genetic diversity.

Underneath San Diego Zoo's Beckman Center for Conservation Research lies the Frozen Zoo, a repository of test tubes containing the genetic material of over 10,000 species. Stacked in towers and chilled inside giant metal vats, the tubes contain the DNA of threatened species from around the world, suspended in time.

It's the largest wildlife biobank in the world.

"Our goal is to opportunistically collect cells ... on multiple individuals of as many species as we can, to provide a vast genetic resource for research and conservation efforts," explains Marlys Houck, curator at the Frozen Zoo.

The Zoo's efforts to save the northern white rhino from extinction have been well publicized. Other research groups have been able to create a northern white rhino embryo in the lab, combining eggs of the last two remaining females with frozen sperm from departed males. Scientists propose implanting those embryos in a surrogate mother of a closely related species, the southern white rhino, to help drag the species back from the edge of oblivion.

For the better part of a decade, conservationists have been focused on this goal, and now their work is paying off: In the "coming months," the lab-created northern white rhino embryo will be implanted in a surrogate.

Sudan, the last male northern white rhinoceros, was euthanized in 2018.

Marisa Korody, a conservation geneticist at the Frozen Zoo, stresses that this type of intervention was really the last hope for the rhino, a species whose population had already diminished to just eight individuals a decade ago.

"We only turn to these methods when more traditional conservation methods have failed," she says.

In Australia, researchers are telling whoever will listen that traditional conservation methods are failing.

"We've been saying for decades and decades, many of our species are on a slippery slope," says John Rodger, a marsupial conservationist at the University of Newcastle, Australia, and CEO of the Fauna Research Alliance, which has long advocated for the banking of genetic material of species in Australia and New Zealand.

In October, 240 of Australia's top scientists delivered a letter to the government detailing the country's woeful record on protecting species, citing the 1,800 plants and animals in danger of extinction, and the "weak" environmental laws which have been ineffective at keeping Australian fauna alive.

Institutions around Australia, such as Taronga Zoo and Monash University, have been biobanking samples since the '90s, reliant on philanthropic donations to stay online, but researchers say this is not enough. For at least a decade, they've been calling for the establishment of a national biobank to support Australia's threatened species.

John Rodger

"Our real problem in Australia ... is underinvestment," Rodger says. "You've got to accept this is not a short-term investment."

The current government installed a threatened-species commissioner in 2017 and committed $255 million ($171 million in US dollars) in funding to improve the prospects of 20 mammal species by 2020. In the most recent progress report, released in 2019, only eight of those 20 were identified as having an "improved trajectory," meaning populations were either increasing faster or declining slower compared to 2015.

A spokesperson for the commissioner outlined the $50 million investment to support immediate work to protect wildlife following the bushfires, speaking to monitoring programs, establishment of "insurance populations" and feral cat traps. No future strategies regarding biobanking were referenced.

Researchers believe we need to act now to preserve iconic Australian species like the koala.

In the wake of the catastrophic bushfire season and the challenges posed by climate change, Australia's extinction crisis is again in the spotlight. Koalas are plastered over social media with charred noses and bandaged skin. On the front page of newspapers, kangaroos bound in front of towering walls of flame.

Houck notes that San Diego's Frozen Zoo currently stores cell lines "from nearly 30 marsupial species, including koala, Tasmanian devil and kangaroo," but that's only one-tenth of the known marsupial species living in Australia today.

"Nobody in the world is seriously working on marsupials but us," Rodger says. "We've got a huge interest in maintaining these guys for tourism, national icons... you name it."

There's a creeping sense of dread in the researchers I talk to that perhaps we've passed a tipping point, not just in Australia, but across the world. "We are losing species at an alarming rate," says Korody from the Frozen Zoo. "Some species are going extinct before we even know they are there."

With such high stakes, Pask and his dunnarts are in a race against time. Perfecting the techniques to genetically engineer the tiny marsupial's cells will help enable the preservation of all marsupial species for generations to come, future-proofing them against natural disasters, disease, land-clearing and threats we may not even be able to predict right now.

Pask reasons "we owe it" to marsupials to develop these tools and, at the very least, biobank their cells if we can't prevent extinction. "We really should be investing in this stuff now," he says. He's optimistic.

In some distant future, years from now, a bundle of frozen stem cells might just bring the koala or the kangaroo back from the brink of extinction.

And for that, we'll have the dunnart to thank.

Originally published Feb. 18, 5 a.m. PT.

Read the original here:

Building a 'doomsday vault' to save the kangaroo and koala from extinction - CNET